[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 259
1. Kadiyska TK, Kaneva RP, Nedin DG, Alexandrova AB, Gegova AT, Lalchev SG, Christova T, Mitev VI, Horst J, Bogdanova N, Kremensky IM: Novel MLH1 frameshift mutation in an extended hereditary nonpolyposis colorectal cancer family. World J Gastroenterol; 2006 Dec 28;12(48):7848-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Besides the typical clinical features of the syndrome, we found a specific pathologic manifestation such as moderate to high differentiated adenocarcinomas of the colon.
  • One of the mutation carriers developed a benign giant cell soft tissue tumor.
  • The primary tumor localizations were frequently extracolonic and detailed yearly gastrointestinal and gynecological examinations have been proposed to the mutation carriers.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Bulgaria. DNA, Neoplasm / genetics. Female. Gene Expression Regulation, Neoplastic. Genetic Counseling. Humans. Male. Microsatellite Instability. Middle Aged. MutS Homolog 2 Protein / genetics. Sequence Deletion / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fam Cancer. 2005;4(3):227-32 [16136382.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):396-404 [15655560.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):208-20 [16434208.001]
  • [Cites] CA Cancer J Clin. 2006 Jul-Aug;56(4):213-25 [16870997.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4285-92 [16908935.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):118-127 [11112663.001]
  • [Cites] Hum Mutat. 2002 Jul;20(1):20-7 [12112654.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):741-9 [12118112.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):837-40 [12378626.001]
  • [Cites] Fam Cancer. 2003;2(1):9-13 [14574162.001]
  • [Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]
  • [Cites] Nature. 1994 Mar 17;368(6468):258-61 [8145827.001]
  • [Cites] Biochim Biophys Acta. 1999 May 31;1423(3):O1-O10 [10382540.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):149-51 [15571801.001]
  • [Cites] Fam Cancer. 2005;4(3):233-7 [16136383.001]
  • (PMID = 17203532.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ PMC4087554
  •  go-up   go-down


2. Mason CK, McFarlane S, Johnston PG, Crowe P, Erwin PJ, Domostoj MM, Campbell FC, Manaviazar S, Hale KJ, El-Tanani M: Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Cancer Ther; 2008 Mar;7(3):548-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this regard, past comparative assaying of the two agents against a range of human tumor cell lines has revealed that typically (-)-agelastatin A is 1.5 to 16 times more potent than cisplatin at inhibiting cell growth, its effects being most pronounced against human bladder, skin, colon, and breast carcinomas.
  • Suppression of Tcf-4 by RNA interference (short interfering RNA) induced malignant/invasive transformation in parental benign Rama 37 cells; significantly, these events were reversed by treatment with (-)-agelastatin A.
  • [MeSH-major] Alkaloids / pharmacology. Cell Adhesion / drug effects. Neoplasm Invasiveness / prevention & control. Osteopontin / physiology. Oxazolidinones / pharmacology
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Humans. Neoplasm Metastasis / prevention & control. Promoter Regions, Genetic. RNA Interference

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347142.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Oxazolidinones; 0 / agelastatin A; 106441-73-0 / Osteopontin
  •  go-up   go-down


3. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL: Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res; 2010;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors.
  • Therefore, we compared ALDH1 expression in normal ovary and benign and malignant ovarian tumors to determine if ALDH1 expression is altered in ovarian cancer.
  • METHODS: mRNA and protein expression were compared in normal human ovary and serous ovarian tumors using quantitative Reverse-Transcriptase PCR, Western blot (WB) and semi-quantitative immunohistochemistry (IHC).
  • RESULTS: ALDH1 mRNA expression was significantly reduced (p < 0.01; n = 5) in malignant tumors compared to normal ovaries and benign tumors.
  • The proportion of ALDH1+ cells was significantly lower in malignant tumors (17.1 ± 7.61%; n = 5) compared to normal ovaries (37.4 ± 5.4%; p < 0.01; n = 5) and benign tumors (31.03 ± 6.68%; p < 0.05; n = 5).
  • ALDH1+ cells occurred in the stroma and surface epithelium in normal ovary and benign tumors, although surface epithelial expression varied more in benign tumors.
  • Localization of ALDH1 was heterogeneous in malignant tumor cells and little ALDH1 expression occurred in poorly differentiated malignant tumors.
  • In benign tumors the distribution of ALDH1 had features of both normal ovary and malignant tumors.
  • CONCLUSIONS: Total ALDH1 expression is significantly reduced in malignant ovarian tumors while it is relatively unchanged in benign tumors compared to normal ovary.
  • Thus, ALDH1 expression in the ovary does not appear to be similar to breast, lung or colon cancer suggesting possible functional differences in these cancers.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Immunol. 2009 Feb;21(1):22-7 [18778953.001]
  • [Cites] Mol Cancer. 2008;7:87 [19025616.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1144-53 [19293794.001]
  • [Cites] Fertil Steril. 2010 Dec;94(7):2636-41 [20522323.001]
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):743-8 [8314353.001]
  • [Cites] J Cell Physiol. 2000 Oct;185(1):1-20 [10942515.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3638-45 [11014218.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Annu Rev Nutr. 2002;22:347-81 [12055350.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Chem Biol Interact. 2003 Feb 1;143-144:201-10 [12604205.001]
  • [Cites] J Biochem Mol Toxicol. 2003;17(1):7-23 [12616643.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1013-20 [12631600.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] FASEB J. 1991 Nov;5(14):2924-33 [1661245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1092-100 [16969345.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3724-33 [17785809.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10538-45 [17974998.001]
  • [Cites] J Cell Sci. 1991 Nov;100 ( Pt 3):657-66 [1808213.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1146-53 [18644979.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):2236-52 [18681906.001]
  • [Cites] Int Immunol. 2009 Apr;21(4):361-77 [19190084.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] Birth Defects Res C Embryo Today. 2009 Mar;87(1):64-89 [19306350.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):817-23 [19329942.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Nucl Recept Signal. 2009;7:e002 [19381305.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] Breast Cancer Res Treat. 2010 Aug;123(1):109-11 [19946740.001]
  • [Cites] Lab Invest. 2010 Feb;90(2):234-44 [20010854.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):876-87 [20103682.001]
  • [Cites] PLoS One. 2010;5(4):e10277 [20422001.001]
  • [Cites] Cell Commun Signal. 2010;8(1):6 [20459772.001]
  • [Cites] J Microsc. 1987 Sep;147(Pt 3):229-63 [3430576.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):146-7 [7707390.001]
  • [Cites] Neurobiol Aging. 1993 Jul-Aug;14(4):275-85 [8367009.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S52-62 [8811064.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):54-62 [9103391.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2033-8 [9815594.001]
  • [Cites] J Investig Med. 1996 Feb;44(2):42-6 [8689400.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2157-63 [12727970.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Mol Cancer. 2004 Oct 7;3:27 [15471544.001]
  • [Cites] J Endocrinol. 2004 Oct;183(1):19-28 [15525570.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):138-43 [16004729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12 [16857736.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jul;72(4):281-9 [17111384.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):340-9 [17920722.001]
  • [Cites] Toxicol Sci. 2008 Jan;101(1):51-64 [17998271.001]
  • [Cites] Endocrinology. 2008 Sep;149(9):4307-11 [18556344.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):697-720 [18611112.001]
  • (PMID = 21176222.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022900
  •  go-up   go-down


Advertisement
4. Kayser K, Hoshang SA, Metze K, Goldmann T, Vollmer E, Radziszowski D, Kosjerina Z, Mireskandari M, Kayser G: Texture- and object-related automated information analysis in histological still images of various organs. Anal Quant Cytol Histol; 2008 Dec;30(6):323-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The procedure was tested for screening of tumor tissue vs. tumor-free tissue in 1,442 cases of various organs.
  • Tissue samples studied include colon, lung, breast, pleura, stomach and thyroid.
  • The algorithm can also distinguish between benign and malignant tumors of colon, between epithelial mesothelioma and pleural carcinomatosis or between different common pulmonary carcinomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160697.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Shantha Kumara HM, Grieco MJ, Yan X, Kalady MF, DiMaggio V, Kim DG, Hyman N, Feingold DL, Whelan RL: Minimally invasive colorectal resection for cancer is associated with a short-lived decrease in soluble Tie-2 receptor levels, which may transiently inhibit VEGF-mediated angiogenesis (via altered blood levels of free Ang-1 and Ang-2). Surg Endosc; 2010 Oct;24(10):2581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After minimally invasive colorectal resection (MICR), Ang-1 levels decrease and Ang-2 levels increase, which may stimulate angiogenesis in wounds and residual tumor foci.
  • METHODS: Blood samples were taken preoperatively (PreOp) and on postoperative days (POD) 1 and 3 from 50 cancer and 53 benign disease MICR patients.
  • RESULTS: PreOp plasma sTie-2 levels were significantly higher in the benign group (27.6 ± 10.2) than in the cancer group (22.9 ± 7.9).
  • A significant drop from PreOp occurred in sTie-2 levels in the cancer group on POD1 (20.0 ± 7.4) and POD3 (21.0 ± 6.6) and in the benign group on POD1 (24.8 ± 9.1).
  • The benign group's POD3 and the cancer group's POD7-13 sTie-2 levels were statistically similar to the PreOp levels while the benign group's POD7-13 level was significantly higher.
  • The benign group's early results were similar.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Aug;25(8):2769-70 [21487885.001]
  • [Cites] J Cell Sci. 2005 Feb 15;118(Pt 4):771-80 [15687104.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] J Am Coll Cardiol. 2004 Feb 4;43(3):423-8 [15013125.001]
  • [Cites] Br J Surg. 2001 Apr;88(4):539-44 [11298622.001]
  • [Cites] Ann Surg. 1966 Sep;164(3):491-502 [5951515.001]
  • [Cites] Eur J Surg Oncol. 2007 Dec;33(10):1169-76 [17512160.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] Br J Surg. 1993 Jun;80(6):777-80 [7687189.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):973-7 [19474682.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 Dec;27(12 ):2619-26 [17901375.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Surgery. 1987 Jul;102(1):71-8 [3495896.001]
  • [Cites] Br J Cancer. 1996 Jul;74(1):69-72 [8679461.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2072-8 [9329972.001]
  • [Cites] Circulation. 2004 Oct 19;110(16):2355-60 [15302795.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):755-64 [16114015.001]
  • [Cites] Eur J Clin Invest. 2003 Jul;33(7):529-35 [12814387.001]
  • [Cites] Surgery. 2004 Aug;136(2):205-9 [15300181.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Eur J Clin Invest. 2006 Feb;36(2):127-32 [16436095.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(8):2011-22 [19223473.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2353-7 [15330184.001]
  • [Cites] Angiogenesis. 2001;4(2):123-31 [11806244.001]
  • [Cites] Surgery. 2003 Sep;134(3):432-6 [14555930.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6571-7 [7987857.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):964-9 [15742397.001]
  • [Cites] J Intern Med. 2005 Oct;258(4):336-43 [16164572.001]
  • [Cites] Br J Surg. 1985 Oct;72(10):771-6 [2412626.001]
  • (PMID = 20354881.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Vascular Endothelial Growth Factors; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


6. Egberts JH, Schafmayer C, Bauerschlag DO, Jänig U, Tepel J: Benign abdominal and pulmonary metastasizing leiomyoma of the uterus. Arch Gynecol Obstet; 2006 Aug;274(5):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign abdominal and pulmonary metastasizing leiomyoma of the uterus.
  • BACKGROUND: Benign metastasizing leiomyoma (BML) is a rare disease in which the lung is described to be the most afflicted extrauterine organ.
  • She was admitted to our hospital for investigation of a huge tumor mass in the pelvis consisting of multiple nodules in the abdomen and left lung.
  • Assuming an advanced intraperitoneal malignancy was present, a 'palliative' limited tumor debulking and due to a tumor compressing the sigmoid a Hartmann's procedure was performed.
  • In the presence of a stable disease after 12 months, the patient underwent a re-laparotomy with a reanastomosis of the colon.
  • CONCLUSIONS: The review of the literature supports the concept that the primary tumor of BML is located in the uterus and that leiomyomas in the uterus can metastasize leading via hematogenous spread to BML.
  • However, the origin of the tumor remains controversial.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16649038.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Benavides MA, Hagen KL, Fang W, Du P, Lin S, Moyer MP, Yang W, Bland KI, Grizzle WE, Bosland MC: Suppression by L-methionine of cell cycle progression in LNCaP and MCF-7 cells but not benign cells. Anticancer Res; 2010 Jun;30(6):1881-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression by L-methionine of cell cycle progression in LNCaP and MCF-7 cells but not benign cells.
  • MATERIALS AND METHODS: MCF-7 (breast), LNCaP (prostate), and LS-174 (colon) cancer cells (wild-type p53), DU-145 (prostate) and SW480 (colon) cancer cells (mutated p53), and immortalized, non-tumorigenic MCF-10A (breast), BPH-1 (prostate), and NCM-460 (colon) epithelial cells were used.
  • LNCaP and MCF-7 cells were arrested at G(1), but DU-145 at S.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biotechnol. 2008 Jun;39(2):113-8 [18327554.001]
  • [Cites] Curr Pharm Des. 2009;15(6):675-81 [19199988.001]
  • [Cites] J Nutr Biochem. 2008 Apr;19(4):207-15 [17707628.001]
  • [Cites] Nucleic Acids Res. 2008 Feb;36(2):e11 [18178591.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):287-96 [17591973.001]
  • [Cites] Am J Surg. 2007 Feb;193(2):274-83 [17236862.001]
  • [Cites] Phytochemistry. 2006 Aug;67(15):1686-98 [16766004.001]
  • [Cites] Med Chem. 2005 May;1(3):227-37 [16787318.001]
  • [Cites] J Biol Chem. 1953 Sep;204(1):403-16 [13084611.001]
  • [Cites] J Biol Chem. 1951 Feb;188(2):723-8 [14824160.001]
  • [Cites] Chem Biol Interact. 1998 Apr 24;111-112:1-14 [9679538.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5193-8 [7693333.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):453-8 [8375929.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4859-65 [2503245.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1409-16 [4357757.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] J Anim Sci. 2002 Aug;80(8):2197-206 [12211390.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Apr 23;11(8):961-4 [11327600.001]
  • [Cites] Cell Mol Life Sci. 2001 Feb;58(2):244-58 [11289306.001]
  • [Cites] Curr Pharm Des. 2009;15(8):893-916 [19275653.001]
  • [Cites] Bioinformatics. 2008 Jul 1;24(13):1547-8 [18467348.001]
  • [Cites] Curr Protoc Protein Sci. 2001 May;Appendix 4:Appendix 4K [18429085.001]
  • (PMID = 20651330.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116195; United States / NCI NIH HHS / CA / R01CA116195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; AE28F7PNPL / Methionine
  • [Other-IDs] NLM/ NIHMS623504; NLM/ PMC4166481
  •  go-up   go-down


8. Pertia A, Nikoleishvili D, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A: Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer. Int Urol Nephrol; 2007;39(2):381-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The importance of cyclin-dependent kinase inhibitors (CDKI) in benign and malignant urological diseases is a subject of intense ongoing investigation.
  • The goal of the current study was to analyze the expression of p27((Kip1))CDKI in benign and malignant renal cells and assess their possible association with different clinical parameters.
  • Intensity of p27((Kip1)) expression in RCC was negatively correlated with tumor size (Rho = -0.438, P = 0.0051) and associated with pathological stage and grade (P = 0.0488 and < 0.0001, respectively).
  • The patients with symptomatic disease had significantly less marker expression than incidentally discovered tumors (P = 0.0301).
  • Loss of p27((Kip1)) expression, pathological stage, grade and tumor size were the risk-factors for disease recurrence (P = 0.0072, 0.0011, 0.0467 and < 0.0001, respectively) and patient survival (P = 0.0021, 0.0106, 0.0151 and 0.0021, respectively).
  • With Cox multivariate analysis loss of p27((Kip1)) expression (hazard ratio 9.3, P = 0.002) and tumor size (hazard ratio 5.9, P = 0.015) were the predictors of cancer-specific survival.
  • Intensity of the expression is associated with clinical parameters: tumor size, stage, grade and disease presentation.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / genetics. Kidney Neoplasms / genetics. Neoplasm Recurrence, Local / genetics

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):601-7 [12448001.001]
  • [Cites] Urology. 2001 Sep;58(3):477-81 [11549509.001]
  • [Cites] In Vivo. 2005 Sep-Oct;19(5):911-20 [16097446.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):3974-86 [15930332.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1245-6 [7489399.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1417-23 [12778072.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):509-17 [15118854.001]
  • [Cites] J Urol. 2005 Jun;173(6):1847 [15879760.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1904-14 [15622584.001]
  • [Cites] Urol Clin North Am. 2003 Aug;30(3):467-80 [12953749.001]
  • [Cites] Nephrol Dial Transplant. 2002 Apr;17(4):573-9 [11917048.001]
  • [Cites] Kidney Int. 2004 Feb;65(2):510-20 [14717921.001]
  • [Cites] BJU Int. 2005 Feb;95(3):310-4 [15679784.001]
  • [Cites] BJU Int. 2005 Mar;95 Suppl 2:8-13 [15759349.001]
  • [Cites] J Urol. 2005 Mar;173(3):680 [15711241.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):631-6 [15517366.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):973-9 [11920465.001]
  • [Cites] FEBS Lett. 2005 Oct 24;579(25):5535-41 [16216245.001]
  • [Cites] Urology. 2004 Sep;64(3):611-6 [15351619.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):992-3 [9307205.001]
  • [Cites] J Urol. 2005 Jun;173(6):1853-62 [15879764.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2266-9 [7757974.001]
  • [Cites] Urology. 2005 Nov;66(5 Suppl):1-9 [16194700.001]
  • (PMID = 17310312.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


9. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Determination of SirT1 function in tumor cells is important for its targeting in cancer therapy.
  • We found that SirT1 knockdown by short hairpin RNA accelerates tumor xenograft formation by HCT116 cells, whereas SirT1 overexpression inhibits tumor formation.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


10. Tsigkou A, Marrelli D, Reis FM, Luisi S, Silva-Filho AL, Roviello F, Triginelli SA, Petraglia F: Total inhibin is a potential serum marker for epithelial ovarian cancer. J Clin Endocrinol Metab; 2007 Jul;92(7):2526-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Total inhibin is the sum of precursors, subunits, and mature molecules of inhibin, which the normal ovary nearly stops to produce after menopause, whereas ovarian tumors still release.
  • 2) benign ovarian tumors (n = 25);.
  • 3) breast (n = 10), colon (n = 10), and stomach (n = 10) cancers; and 4) controls (n = 95).
  • In the group of women with epithelial ovarian cancer, blood specimens were also collected after surgical removal of the tumor.
  • In four cases of women with stage IIC mucinous tumor, blood specimens were collected during the follow-up time.
  • RESULTS: Women with epithelial ovarian cancers showed serum total inhibin levels significantly higher than those with benign tumor or with nonovarian tumors or controls (P < 0.001).
  • Patients with serous (n = 40) or mucinous tumors (n = 17) showed the highest total inhibin levels (P < 0.001).
  • At 95% specificity, the total inhibin assay detected 37 of 40 (93%) serous tumors and 16 of 17 (94%) mucinous tumors.
  • When total inhibin was combined with CA-125, all cases of serous and mucinous tumors were detected, and the overall sensitivity for epithelial ovarian cancers was 99% at 95% specificity.
  • [MeSH-major] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / blood. Immunoenzyme Techniques / methods. Inhibins / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473066.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 57285-09-3 / Inhibins
  •  go-up   go-down


11. Chiang JM, Lin YS: Tumor spectrum of adult intussusception. J Surg Oncol; 2008 Nov 1;98(6):444-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor spectrum of adult intussusception.
  • Neoplasm was identified as the cause of intussusception in 66 (92%) cases, and 6 (8%) were idiopathic.
  • The incidence of malignant colonic intussusception (63%) was significantly higher than that of enteric intussusception (20%), P = 0.001.
  • Primary colon adenocarcinoma (8 of 10 patients, 80%) and malignant lymphoma (2 of 10 patients, 20%) were the two most common underlying malignant lesions in the colon.
  • Lipoma (15 of 40 patients, 38%) and Peutz-Jegher adenoma (10 of 40 patients, 25%) were the two most common lesions of benign small bowel neoplasms while 27% (3 of 11) of malignant enteric intussusception cases were malignant lymphoma and metastatic respectively.
  • CONCLUSION: Lipoma is the most common benign tumor in both small and large bowel intussusception.
  • Whereas 80% of tumors associated with small bowel intussusception were benign, two-thirds of colonic intussusceptions had resulted from primary adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] J Surg Oncol. 2009 Jun 1;99(7):457
  • (PMID = 18668640.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Bölke E, Krasniqi H, Lammering G, Engers R, Matuschek C, Gripp S, Gerber PA, Fischer G, Peiper M, Shaikh S, Budach W, Orth K: Chest wall and intrathoracic desmoid tumors: surgical experience and review of the literature. Eur J Med Res; 2009 Jun 18;14(6):240-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chest wall and intrathoracic desmoid tumors: surgical experience and review of the literature.
  • Desmoid tumors are fibroblastic/myofibroblastic neoplasms, which originate from musculo-aponeurotic structures and are classified as deep fibromatoses.
  • Despite their benign histologic appearance and lack of metastatic potential, desmoid tumors may cause aggres?sive local infiltrations and compression of surrounding structures.
  • Radical tumor resection with free margins remains the first therapy of choice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Apr 1;88(7):1517-23 [10738207.001]
  • [Cites] J Thorac Oncol. 2008 Jun;3(6):656-9 [18520808.001]
  • [Cites] Br J Surg. 2002 Dec;89(12):1563-9 [12445067.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1219-23; discussion 1219-23 [15464474.001]
  • [Cites] Br J Surg. 1971 Jul;58(7):495-8 [4253594.001]
  • [Cites] S Afr J Surg. 1971 Jul-Sep;9(3):133-40 [5138518.001]
  • [Cites] J Thorac Cardiovasc Surg. 1985 Sep;90(3):367-72 [4033174.001]
  • [Cites] Am J Med Genet. 1987 Oct;28(2):385-92 [2827474.001]
  • [Cites] Am J Surg. 1990 May;159(5):450-3 [2139764.001]
  • [Cites] Hum Mol Genet. 1995 Mar;4(3):337-40 [7795585.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):659-65 [9336146.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1007-14 [9869223.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1999 Jul;11(3):264-9 [10451258.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):158-67 [10458229.001]
  • [Cites] Gut. 2004 Dec;53(12):1832-6 [15542524.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):882-91 [15708271.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1275-81 [15793634.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jan;186(1):247-54 [16357411.001]
  • [Cites] Histol Histopathol. 2008 Jan;23(1):117-26 [17952864.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):441-7 [18068311.001]
  • [Cites] Eur J Surg Oncol. 2001 Dec;27(8):701-6 [11735163.001]
  • (PMID = 19541583.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC3352015
  •  go-up   go-down


13. Jung MK, Cho CM, Park SY, Jeon SW, Tak WY, Kweon YO, Kim SK, Choi YH: Endoscopic resection of ampullary neoplasms: a single-center experience. Surg Endosc; 2009 Nov;23(11):2568-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An ampullary tumor, whether malignant or not, must be completely resected.
  • A benign adenoma has the potential for malignant transformation.
  • Currently, endoscopic papillectomy with curative intent is increasingly performed for benign papillary tumors.
  • This study aimed to evaluate the outcome of endoscopic papillectomy performed for ampullary tumors at a single center.
  • METHODS: From July 2003 to June 2008, 22 patients with a diagnosis of ampullary tumors determined by endoscopic retrograde cholangiopancreatography (ERCP) were treated using endoscopic resection of the tumors.
  • Endoscopic resection was performed in a radical fashion analogous to polypectomy for colon adenomas.
  • CONCLUSIONS: The findings showed that an endoscopic papillectomy was safe and effective for benign-appearing adenomas with negative biopsy results for a malignancy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Chi-Square Distribution. Cohort Studies. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Pancreaticoduodenectomy / methods. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Probability. Reoperation / methods. Retrospective Studies. Risk Assessment. Sphincterotomy, Endoscopic / adverse effects. Sphincterotomy, Endoscopic / methods. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2006 May;38(5):521-5 [16767591.001]
  • [Cites] Surg Endosc. 2006 Apr;20(4):608-13 [16508819.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Surgery. 1987 Apr;101(4):501-4 [3563897.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):161-7 [2471581.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):367-70 [16111953.001]
  • [Cites] South Med J. 1989 Jul;82(7):917-20 [2665132.001]
  • [Cites] Surg Gynecol Obstet. 1989 Nov;169(5):445-8 [2683151.001]
  • [Cites] Endoscopy. 1988 Aug;20 Suppl 1:227-31 [3168951.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):799-819 [7248908.001]
  • [Cites] Am Surg. 1990 Apr;56(4):214-7 [2194412.001]
  • [Cites] Ann Surg. 1987 Sep;206(3):358-65 [3632096.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):187-200 [17245171.001]
  • [Cites] Am J Gastroenterol. 1992 Jan;87(1):37-42 [1728122.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):789-91 [16650539.001]
  • [Cites] Gastrointest Endosc. 2001 Aug;54(2):202-8 [11474391.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] Gastrointest Endosc. 1991 May-Jun;37(3):383-93 [2070995.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):757-64 [15557951.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):783-8 [16650538.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • (PMID = 19360365.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Königsrainer I, Steurer W, Witte M, Königsrainer A: Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis. Langenbecks Arch Surg; 2007 Jul;392(4):485-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis.
  • Extrahepatic isolation of portal vein, hepatic artery and hepatic duct, as well as lymphadenectomy of the liver hilum are generally accepted steps of liver resection, even for metastatic and benign indications.
  • MATERIALS AND METHODS: Thirty-eight consecutive patients with resection for metastases and benign liver tumors were selected.
  • To date, no tumor recurrence was found in the hilum during the follow-up period.
  • Hilar dissection can, thus, be avoided in liver metastasis and benign liver tumors.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1285-90; discussion 1290-1 [10528765.001]
  • [Cites] J Surg Oncol. 2005 Apr 1;90(1):43-5 [15786414.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):137-8; author reply 138 [16371749.001]
  • [Cites] Ann Surg. 2005 Apr;241(4):582-90 [15798459.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):685-9 [16703653.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):286-91 [9880776.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):202-9 [14745328.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):260-4 [16858189.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):111-9 [12832973.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):764-7 [7571678.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):45-50 [11141224.001]
  • [Cites] Ann Surg. 1996 Aug;224(2):155-61 [8757378.001]
  • [Cites] Ann Surg. 1997 Dec;226(6):704-11; discussion 711-3 [9409569.001]
  • [Cites] World J Gastroenterol. 2006 Feb 14;12(6):935-9 [16521223.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):942-5 [8813780.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):121-4 [8653335.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):210-5 [10024102.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):814-22, discussion 822-3 [16327491.001]
  • (PMID = 17530278.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Mercier I, Vuolo M, Jasmin JF, Medina CM, Williams M, Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP, Kitsis RN: ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle; 2008 Jun 1;7(11):1640-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer.
  • Recently, however, the abundance of ARC was noted to be markedly increased in the epithelium of primary human breast cancers compared with benign breast tissue and to confer chemo- and radiation-resistance.
  • Whether the induction of ARC is specific to breast cancer or a more general feature of neoplasia remains unknown.
  • In this study, we assessed the abundance and subcellular localization of ARC in 21 human colon cancer cell lines and in 44 primary human colon adenocarcinomas and adjacent benign colonic tissue.
  • ARC was present at high levels in most colon cancer cell lines and in almost all primary colon cancers compared with corresponding controls.
  • Levels of ARC in the cytoplasm were increased in well, moderately, and poorly differentiated cancers compared with benign tissue, while levels of nuclear ARC were increased only in moderately differentiated tumors.
  • These results demonstrate that ARC is a novel marker of human colon cancer and suggest that it may be a general feature of epithelial cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis Regulatory Proteins / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / metabolism. Muscle Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. Cytoplasm / metabolism. Humans. Immunoblotting. Immunohistochemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469522.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-098779; United States / NCI NIH HHS / CA / R01-CA-120876; United States / NCI NIH HHS / CA / R01-CA-80250; United States / NHLBI NIH HHS / HL / R01HL60665; United States / NHLBI NIH HHS / HL / R01HL61550; United States / NHLBI NIH HHS / HL / R01HL80607
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Muscle Proteins; 0 / NOL3 protein, human
  •  go-up   go-down


16. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer; 2008 May-Jun;18(3):506-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer stem cells have been isolated from several solid tumors including prostate, colon, liver, breast, and ovarian cancer.
  • The aims of this study were to investigate the expression of the CD133-1 and CD133-2 epitopes in primary ovarian tumors and to biologically characterize CD133(+) ovarian cancer cells, also according to clinicopathologic parameters.
  • Tissue specimens were obtained at primary surgery from 41 ovarian carcinomas; eight normal ovaries and five benign ovarian tumors were also collected.
  • The percentages of CD133-1- and CD133-2-expressing cells were significantly lower in normal ovaries/benign tumors with respect to those in ovarian carcinoma.
  • CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133(+) ovarian tumor cells, which are characterized by a higher clonogenic efficiency and proliferative potential.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Glycoproteins / metabolism. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868344.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


17. Arnold CN, Nagasaka T, Goel A, Scharf I, Grabowski P, Sosnowski A, Schmitt-Gräff A, Boland CR, Arnold R, Blum HE: Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. Int J Cancer; 2008 Oct 1;123(7):1556-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors.
  • To better understand the molecular pathogenesis of neuroendocrine tumors (NET), we investigated the molecular and clinical characteristics of malignant poorly differentiated colorectal NET and compared these findings with sporadic CRC and well-differentiated benign and malignant fore-/midgut NET.
  • Tumors were analyzed and correlated for microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP).
  • A total of 34 malignant poorly differentiated colorectal NET, 38 well-differentiated benign and malignant fore-/midgut-NET and 150 sporadic colorectal cancers (CRC) with known MSI status were investigated.
  • Of the 34 colorectal NET, 0/1 of the MSI-H, 3/5 (60%) of the MSI-L and 13/19 (68%) of the MSS tumors were CIMP+ (p = 0.17).
  • Besides the location in the colon, Ki-67 predicted poor outcome in NET (p < 0.0001).
  • Main differences between malignant well-differentiated and poorly differentiated NET are the Ki-67 proliferation rate and differential methylation in tumor-associated genes.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Colorectal Neoplasms / mortality. Neuroendocrine Tumors / genetics. Neuroendocrine Tumors / mortality

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):947-57 [14871972.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2157-64 [17278096.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:199-208 [15153435.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):805-15 [15459661.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Nat Med. 1996 Mar;2(3):281-2 [8612223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2545-50 [9122232.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):50-6 [9591634.001]
  • [Cites] Lancet. 1997 Oct 25;350(9086):1223 [9652567.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):11-6 [10389971.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):855-60 [15613458.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):256-60 [15842051.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):145-9 [18058263.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):38-45 [11790979.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Feb;15(2):139-43 [12560757.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):924-34 [12584572.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):1367-73 [12629131.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Diagn Mol Pathol. 2003 Dec;12(4):181-6 [14639103.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):570-6 [10747315.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):549-56 [10998653.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1097-103 [11021813.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4073-81 [11051259.001]
  • [Cites] Oncology. 2000 Sep;59(3):229-37 [11053991.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4146-56 [11095446.001]
  • [Cites] Gut. 2001 Apr;48(4):536-41 [11247899.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11 [11338071.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5905-10 [11479232.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Neuroendocrinology. 2005;81(1):1-9 [15809513.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Aug;3(8):761-71 [16234004.001]
  • [Cites] Int J Colorectal Dis. 2006 Apr;21(3):221-30 [16485142.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • (PMID = 18646189.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072851; United States / NCI NIH HHS / CA / R01 CA072851-13
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS187521; NLM/ PMC2851204
  •  go-up   go-down


18. Yeh CJ, Chuang WY, Chou HH, Jung SM, Hsueh S: Multiple extragenital adenomatoid tumors in the mesocolon and omentum. APMIS; 2008 Nov;116(11):1016-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple extragenital adenomatoid tumors in the mesocolon and omentum.
  • Adenomatoid tumors are benign mesothelial neoplasms most commonly found in the male and female genital tracts.
  • Extragenital adenomatoid tumors are rare, most of them being solitary tumors.
  • To our knowledge, only one case of multiple extragenital adenomatoid tumors, involving the liver and peritoneum, has been reported to date.
  • Here we report another case of multiple extragenital adenomatoid tumors involving the mesocolon and omentum.
  • The patient was transferred to our hospital without resection due to the intraoperative finding of multiple peritoneal tumors.
  • At our hospital, an 8.0x7.5x6.0 cm tumor at the mesocolon of the sigmoid colon and three omental nodules measuring up to 2.5x2.0x1.7 cm were resected.
  • Immunohistochemically, the tumor cells were positive for pan-cytokeratin AE1/AE3, vimentin, cytokeratin 5/6 and calretinin.
  • Despite their rarity, adenomatoid tumors should be included in the differential diagnosis of multiple intra-abdominal tumors.
  • [MeSH-major] Adenomatoid Tumor / pathology. Mesocolon / pathology. Neoplasms, Multiple Primary / pathology. Omentum / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133002.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


19. Shantaram M, Rao A, Aroor AR, Raja A, Rao S, Monteiro F: Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors. Ann Indian Acad Neurol; 2009 Jul;12(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors.
  • BACKGROUND: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression.
  • The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors.
  • But there are very few reports available on the serum glycoconjugate levels in patients with brain tumors.
  • OBJECTIVE: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients.
  • MATERIALS AND METHODS: Colorimetric estimation of TSA using diphenylamine was done on 100 patients with intracranial tumors; follow-up study was carried out in 24 cases.
  • The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients.
  • The various types of brain tumors included in this study were glioma, meningioma, and acoustic neurinoma as well as some other types such as medulloblastoma, secondary tumors, and craniopharyngioma.
  • DISCUSSION: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors.
  • TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 1992;24(2):125-9 [1624255.001]
  • [Cites] Cancer Lett. 1991 Jun 14;58(1-2):91-100 [2049789.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Aug;49(8):843-7 [2072195.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):139-42 [2298100.001]
  • [Cites] Adv Cancer Res. 1989;52:257-331 [2662714.001]
  • [Cites] Bull Soc Sci Med Grand Duche Luxemb. 1989 Mar-Apr;126(1):17-20 [2663215.001]
  • [Cites] Thyroid. 2005 Jul;15(7):645-52 [16053379.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):535-9 [15885233.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):912-7 [10841826.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1980 Oct;30(1):171-80 [7433766.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1815-9 [7116306.001]
  • [Cites] Clin Biochem. 1980 Oct;13(5):191-7 [7006855.001]
  • [Cites] Anticancer Res. 1984 Jul-Oct;4(4-5):313-6 [6486735.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1389-94 [3948121.001]
  • [Cites] Int J Biol Markers. 1988 Oct-Dec;3(4):243-8 [3235852.001]
  • [Cites] Clin Chim Acta. 1988 Sep 15;176(3):251-7 [3180477.001]
  • [Cites] Neurol Res. 1986 Jun;8(2):123-6 [2875407.001]
  • [Cites] Obstet Gynecol. 1988 Jan;71(1):20-6 [2827081.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1780(3):421-33 [17991443.001]
  • (PMID = 20174496.001).
  • [ISSN] 1998-3549
  • [Journal-full-title] Annals of Indian Academy of Neurology
  • [ISO-abbreviation] Ann Indian Acad Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2824932
  • [Keywords] NOTNLM ; Brain tumors / lipid-bound sialic acid / total sialic acid / tumor markers
  •  go-up   go-down


20. Goh BK, Chow PK, Kesavan S, Yap WM, Ong HS, Song IC, Eu KW, Wong WK: Intraabdominal schwannomas: a single institution experience. J Gastrointest Surg; 2008 Apr;12(4):756-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Intraabdominal schwannomas are rare, benign tumors.
  • This study presents a single institution experience with 12 such tumors.
  • METHODS: Between 1991 to 2006, 12 patients with a pathologically proven intraabdominal schwannoma were identified from a series of 216 mesenchymal tumors and were reviewed retrospectively.
  • Eleven patients were symptomatic, and the tumors were located in the stomach (n = 8), jejunum, colon, rectum, and lesser sac.
  • The median tumor size was 52 mm (range 18-95 mm).
  • Pathological examination demonstrated the 11 gastrointestinal tract (GIT) schwannomas to be solid homogenous tumors, which were highly cellular and were composed of spindle cells with positive staining for S100 protein.
  • CONCLUSION: Intraabdominal schwannomas are rare tumors, which are most frequently located within the GIT.
  • The treatment of choice is complete surgical excision because of diagnostic uncertainty, and the long-term outcome is excellent as these lesions are uniformly benign.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):207-16 [7530409.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):846-55 [11420455.001]
  • [Cites] Ann Acad Med Singapore. 2006 Jan;35(1):45-8 [16470274.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Oct;125(2):391-4 [1200238.001]
  • [Cites] Clin Radiol. 1996 Jul;51(7):517-8 [8689831.001]
  • [Cites] Hum Pathol. 1988 Mar;19(3):257-64 [3126126.001]
  • [Cites] Am Surg. 1993 May;59(5):293-6 [8489097.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Radiology. 2003 Feb;226(2):527-32 [12563150.001]
  • [Cites] AJR Am J Roentgenol. 2005 Mar;184(3):797-802 [15728600.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):539-43 [17762560.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):431-6 [10199472.001]
  • [Cites] Hepatogastroenterology. 1998 Sep-Oct;45(23):1764-6 [9840143.001]
  • [Cites] Langenbecks Arch Surg. 2006 Aug;391(4):322-9 [16402273.001]
  • [Cites] Histopathology. 2006 Apr;48(5):536-45 [16623779.001]
  • [Cites] Aust N Z J Surg. 1995 Mar;65(3):197-200 [7887865.001]
  • [Cites] Br J Radiol. 1997 Sep;70(837):952-5 [9486074.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1275-8 [17451214.001]
  • [Cites] Pathol Res Pract. 2002;198(9):605-13 [12440783.001]
  • [Cites] Histopathology. 1995 Oct;27(4):355-60 [8847066.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23 (2):283-304, 456; quiz 532 [12640147.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):304-8 [9042794.001]
  • [Cites] Am J Surg. 2006 Jul;192(1):14-8 [16769268.001]
  • [Cites] J Ultrasound Med. 2004 Nov;23 (11):1527-30 [15498921.001]
  • [Cites] Dig Surg. 2006;23(4):265-9 [17035701.001]
  • (PMID = 18074186.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Prenzel KL, Schäfer E, Stippel D, Beckurts KT, Hölscher AH: Multiple giant leiomyomas of the esophagus and stomach. Dis Esophagus; 2006;19(6):504-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leiomyomas are rare esophageal disorders, although among the benign esophageal neoplasms, they are the most common.
  • On endoscopy multiple nodules covered with intact mucosa were present, the largest tumor arising from the gastro-esophageal border infiltrating the cardia.
  • Barium swallow demonstrated narrowing of the middle and lower esophagus with the upper third of the stomach filled by the tumor.
  • Thorax and abdominal CT scans revealed infiltration of almost the total aboral esophagus by the tumor with compression of left and right bronchi.
  • Due to the extended tumor growth with infiltration of the upper third of the stomach, a total esophago-gastrectomy with reconstruction by colon interposition was performed.
  • Immunohistochemically the tumor stained positive for desmin and sm-actin and negative for CD34 and c-kit.
  • In young patients with diffuse multinodular infiltration by encapsulated tumors, esophageal leiomyomatosis should be considered.
  • If the proximal third of the stomach is infiltrated by the tumor an extended resection is necessary.
  • Reconstruction procedures include colon interposition.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069596.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / COL4A5 protein, human; 0 / Collagen Type IV
  •  go-up   go-down


22. Beatty JS, Williams HT, Aldridge BA, Hughes MP, Vasudeva VS, Gucwa AL, David GS, Lind DS, Kruse EJ, McLoughlin JM: Incidental PET/CT findings in the cancer patient: how should they be managed? Surgery; 2009 Aug;146(2):274-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 133 patients evaluated further, clinicians identified a second primary malignancy in 41 patients (31%), benign disease in 62 patients (47%), and metastatic disease from their known malignancy in 30 patients (23%).
  • The most common sites for a proven second primary malignancy were: lung (N = 10), breast (N = 7), and colon (N = 5).
  • In our data, approximately half of these findings were benign, a third were consistent with a second primary malignancy or a metastatic focus, and the remainder were never evaluated due to physician and patient decision.
  • Advanced primary tumors are unlikely to be impacted by a second primary tumor suggesting that this subset of patients will not benefit from further investigation.
  • The timing and route of investigation should be dictated by clinical judgment and the status of the primary tumor.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628085.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Atallah S, Albert M, Larach S: Transanal minimally invasive surgery: a giant leap forward. Surg Endosc; 2010 Sep;24(9):2200-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the clinical application of this technique and present preliminary data that show TAMIS to be an effective tool for resection of both malignant and benign lesions of the rectum.
  • Patients with biopsy-proven malignant lesions were required to undergo endorectal ultrasound preoperatively to determine tumor stage.
  • The average distance from the anal verge was 9.3 cm and the mean tumor diameter confirmed by pathology measured 2.93 cm.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Biopsy. Endosonography. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]
  • [Cites] World J Surg. 2009 May;33(5):1015-9 [19116734.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):601-4 [12004207.001]
  • [Cites] Dis Colon Rectum. 2009 Jun;52(6):1107-13 [19581854.001]
  • [Cites] Colorectal Dis. 2007 Jul;9(6):553-8 [17573752.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Surg Endosc. 2009 Jul;23(7):1419-27 [19347400.001]
  • [Cites] Surg Endosc. 2010 Feb;24(2):445-9 [19565297.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Asian J Surg. 2006 Oct;29(4):227-32 [17098653.001]
  • [Cites] Gastrointest Endosc. 2009 Jul;70(1):193-4 [19559847.001]
  • [Cites] Leber Magen Darm. 1985 Nov;15(6):271-9 [4079630.001]
  • [Cites] J Gastrointest Surg. 2009 Sep;13(9):1733-40 [19412642.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1376-80 [14571741.001]
  • [Cites] Minerva Chir. 2009 Aug;64(4):355-64 [19648856.001]
  • [Cites] Surg Technol Int. 2009 Apr;18:19-25 [19579186.001]
  • [Cites] Urology. 2009 Oct;74(4):805-12 [19643465.001]
  • [Cites] Colorectal Dis. 2006 Nov;8(9):795-9 [17032328.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Int Semin Surg Oncol. 2006 May 04;3:13 [16674824.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Dec;10(6):372-8 [11147912.001]
  • [Cites] Colorectal Dis. 2007 Mar;9(3):229-34 [17298620.001]
  • [Cites] Ann Surg. 2009 May;249(5):776-82 [19387326.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2009 Aug;19(4):495-9 [19630589.001]
  • [Cites] Surg Endosc. 2009 May;23(5):1138-41 [19263120.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Arch Surg. 2009 Feb;144(2):173-9; discussion 179 [19221330.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 20174935.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Nau P, Melvin WS, Narula VK, Bloomston PM, Ellison EC, Muscarella P: Laparoscopic distal pancreatectomy with splenic conservation: an operation without increased morbidity. Gastroenterol Res Pract; 2009;2009:846340
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The advent of minimally invasive techniques was marked by a paradigm shift towards the use of laparoscopy for benign distal pancreatic masses.
  • The mean tumor size was not significantly different (3.1 versus 2.2 cm, P = .9).
  • Complications in the spleen-preserving group included one iatrogenic colon injury, two pancreatic fistulas, and two cases of iatrogenic diabetes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1991 Aug;78(8):976-9 [1913121.001]
  • [Cites] Am Surg. 2008 Jun;74(6):481-6; discussion 486-7 [18556989.001]
  • [Cites] Ann Surg. 1990 Jan;211(1):60-2 [2294845.001]
  • [Cites] Am Surg. 1989 Jan;55(1):21-5 [2913905.001]
  • [Cites] J Am Coll Surg. 1999 Mar;188(3):255-60 [10065814.001]
  • [Cites] Ann Surg. 1999 May;229(5):693-8; discussion 698-700 [10235528.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):149-58 [12170019.001]
  • [Cites] Surg Endosc. 2004 Mar;18(3):407-11 [14752628.001]
  • [Cites] Clin Anat. 2004 Sep;17(6):497-502 [15300870.001]
  • [Cites] J Gastrointest Surg. 2005 May-Jun;9(5):733-8 [15862272.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Surg Endosc. 2005 Aug;19(8):1028-34 [16027987.001]
  • [Cites] Surg Endosc. 2007 Apr;21(4):579-86 [17180287.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):373-7 [17180289.001]
  • [Cites] Surgery. 2007 May;141(5):619-25 [17462461.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):77-82 [17592294.001]
  • [Cites] Surg Endosc. 2007 Dec;21(12):2326-30 [17593458.001]
  • [Cites] J Gastrointest Surg. 2008 Jul;12(7):1202-6 [18437500.001]
  • [Cites] Br J Surg. 1991 Sep;78(9):1031-8 [1933181.001]
  • (PMID = 20049337.001).
  • [ISSN] 1687-630X
  • [Journal-full-title] Gastroenterology research and practice
  • [ISO-abbreviation] Gastroenterol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2798083
  •  go-up   go-down


25. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med; 2009 Sep;1(6-7):338-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion.
  • Human colon cancers often start as benign adenomas through loss of APC, leading to enhanced beta CATENIN (beta CAT)/TCF function.
  • We find that epithelial cells of human colon carcinomas (CCs) and their stem cells of all stages harbour an active HH-GLI pathway.
  • Moreover, using a novel tumour cell competition assay we show that the self-renewal of CC stem cells in vivo relies on HH-GLI activity.
  • Targeting HH-GLI1, directly or indirectly, is thus predicted to decrease tumour bulk and eradicate CC stem cells and metastases.
  • [MeSH-major] Carcinoma / metabolism. Colonic Neoplasms / metabolism. Epithelial Cells / metabolism. Hedgehog Proteins / metabolism. Neoplastic Stem Cells / cytology. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cells, Cultured. Gene Expression Regulation, Neoplastic. Humans. Mice. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Signal Transduction / drug effects. Veratrum Alkaloids / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):117-23 [16473672.001]
  • [Cites] Virchows Arch. 2009 Apr;454(4):369-79 [19280222.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Development. 2004 Jan;131(2):337-45 [14681189.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] J Pathol. 2004 Aug;203(4):909-17 [15258993.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):257-75 [15328011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Teratology. 1970 May;3(2):175-80 [4986632.001]
  • [Cites] Lipids. 1978 Oct;13(10):708-15 [723484.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Development. 1999 Jun;126(14):3205-16 [10375510.001]
  • [Cites] Development. 2005 Jan;132(2):279-89 [15590741.001]
  • [Cites] Mech Dev. 2005 Feb;122(2):223-30 [15652709.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2187-2194.e1 [19324043.001]
  • [Cites] Surgery. 2006 May;139(5):665-70 [16701100.001]
  • [Cites] Gut. 2006 Jul;55(7):991-9 [16299030.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1238-9 [17287906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] World J Gastroenterol. 2007 Mar 21;13(11):1659-65 [17461467.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2622-7 [17683069.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):281-3 [18835029.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):603-7 [19092805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] EMBO J. 2009 Mar 18;28(6):663-76 [19214186.001]
  • [CommentIn] EMBO Mol Med. 2010 Oct;2(10):385-6; author reply 386-7 [20721989.001]
  • [CommentIn] EMBO Mol Med. 2009 Sep;1(6-7):300-2 [20049733.001]
  • (PMID = 20049737.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC3378144
  •  go-up   go-down


26. Nowicki MJ, Bishop PR, Subramony C, Wyatt-Ashmead J, May W, Crawford M: Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion. J Pediatr Gastroenterol Nutr; 2005 Nov;41(5):600-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion.
  • Colonic polyps are common both in adults and children; however, the malignant potential varies according to the type of polyp.
  • To determine whether CSM represents a preneoplastic lesion, we studied endoscopic colonic mucosal biopsies for markers of cell replication (Ki-67) and malignant transformation (p53) in mucosal biopsies of CSM, normal colonic tissue, tubular adenomas, and adenocarcinomas.
  • The degree of Ki-67-positive staining cells was similar for CSM and normal colonic tissue, whereas there was significantly increased staining for both tubular adenomas and adenocarcinomas.
  • There was no evidence of p53 staining in CSM and normal colonic mucosa, whereas there was varying degrees of staining in tubular adenomas and adenocarcinomas.
  • The association of CSM with benign juvenile polyps and the absence of histologic markers for increased replication and malignant transformation support the notion that this endoscopic finding is not preneoplastic.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Intestinal Mucosa / pathology. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Child. Child, Preschool. Colon / pathology. Colonoscopy. Female. Humans. Immunohistochemistry. Male. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254516.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


27. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
  • In tumors of the female genital tract, L1 was detected in adenocarcinomas of the cervix and fallopian tubes, in addition to ovarian and endometrial carcinomas.
  • Nongynecological tumors expressing L1 comprised malignant melanoma, colon adenocarcinoma positive to chromogranin, clear-cell adenocarcinoma of the urinary bladder, pheochromocytoma, small cell lung carcinoma, and tumors of the nervous system.
  • Surprisingly, L1 expression in established breast and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


28. Zmora O, Benjamin B, Reshef A, Neufeld D, Rosin D, Klein E, Ayalon A, Shpitz B: Laparoscopic colectomy for colonic polyps. Surg Endosc; 2009 Mar;23(3):629-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for colonic polyps.
  • BACKGROUND: Benign colonic polyps not amenable to colonoscopic resection or those containing carcinoma require surgical excision.
  • The aim of this study was to review our experience with the laparoscopic approach for retrieval of colonic polyps with specific emphasis on safety, feasibility, and tumor localization.
  • METHODS: Retrospective chart review of all patients who underwent laparoscopic colectomy for colonic polyps was performed.
  • RESULTS: Forty-nine patients (22 males, 27 males, mean age 66 years) underwent laparoscopic colectomy for colonic polyps.
  • Indications for surgery were presumably benign polyps in 38 patients, and superficial carcinoma in a polyp, diagnosed by colonoscopy, in 11; twenty-three patients underwent preoperative localization procedures.
  • In 7 of the 38 patients with presumably benign lesion, colon cancer was diagnosed in the colectomy specimen.
  • CONCLUSIONS: Laparoscopic surgery for the treatment of colonic polyps seems to be feasible and safe, with a low complication rate.
  • Tumor localization is crucial for adequate resection.
  • Although one-fifth of presumably benign polyps harbored cancer, none of these patients had positive lymph nodes.
  • [MeSH-major] Colectomy / methods. Colonic Polyps / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2006 Apr;30(4):605-11 [16555023.001]
  • [Cites] Surg Endosc. 2002 May;16(5):808-11 [11997827.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1111-24 [15449261.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):177-81 [12892794.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1491-5 [17534547.001]
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1353-5 [10528779.001]
  • [Cites] Ann Surg. 2006 Jun;243(6):730-5; discussion 735-7 [16772776.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003145 [16034888.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1197-9 [18062067.001]
  • [Cites] Dis Colon Rectum. 1999 Jun;42(6):819-22 [10378609.001]
  • [Cites] Am J Surg. 2006 Nov;192(5):644-8 [17071200.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • (PMID = 19067054.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


29. Ishikawa K, Hirashita T, Araki K, Kitano M, Matsuo S, Matsumata T, Kitano S: A case of retroperitoneal mucinous cystadenoma treated successfully by laparoscopic excision. Surg Laparosc Endosc Percutan Tech; 2008 Oct;18(5):516-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found a smooth and thin-walled cystic tumor that displaced the descending colon to the right and arose from the retroperitoneum, loosely adhering to the psoas muscle.
  • We successfully extirpated the tumor laparoscopically.
  • The histologic diagnosis was benign mucinous cystadenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936681.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Pagnotta E, Calonghi N, Boga C, Masotti L: N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells. Anticancer Drugs; 2006 Jun;17(5):521-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells.
  • Both agents show the same anti-proliferative effects by arresting colon cancer cell growth in G0/G1.
  • The effects of NMF and 9-HSA on growth, differentiation and invasiveness of HT29, a colon cancer cell line, have been compared by using immunoprecipitation analysis, confocal microscopy, enzyme assays and invasiveness tests.
  • Evidence is presented that the arrest in early G0/G1 induced by 9-HSA is associated with the conversion of HT29 characteristics to those of a more benign phenotype, whereas the arrest in the late G1 in response to NMF is not followed by a decrease in tumorigenicity.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Formamides / pharmacology. Stearic Acids / pharmacology
  • [MeSH-minor] Cell Cycle / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cytoskeleton / drug effects. Humans. Microscopy, Confocal

  • Hazardous Substances Data Bank. N-METHYLFORMAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702808.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Formamides; 0 / Stearic Acids; 3384-24-5 / 9-hydroxystearic acid; XPE4G7Y986 / methylformamide
  •  go-up   go-down


31. Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ: Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol; 2009 Mar;34(3):821-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated levels of periostin have been implicated as playing important roles in tumor invasion and metastasis in various tissues.
  • We also evaluated periostin expression in human CRC specimens (n=15) using immunohistochemistry, and measured expression of periostin mRNA in 7 CRC tissue samples, matched normal tissues and in 4 colon cancer cell lines by RT-PCR.
  • The serum levels of periostin in CRC patients (40.9+/-15.4 ng/ml) were significantly elevated compared to that in healthy volunteers (21.0+/-7.3 ng/ml, P<0.0001) and benign colorectal polyps or adenomas (22.4+/-8.5 ng/ml, P<0.0001).
  • Interestingly, periostin mRNA was highly upregulated in CRCs in comparison with matched normal tissues, and no expression of periostin mRNA was detected in 4 colon cancer cell lines.
  • Periostin may be produced by the stromal cells surrounding the tumor, but not by the CRC cells themselves.
  • [MeSH-major] Biomarkers, Tumor / blood. Cell Adhesion Molecules / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212687.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / RNA, Messenger
  •  go-up   go-down


32. Krzysztof K, Wiktor B, Tadeusz Ł, Waldemar B, Magdalena K, Janusz D: Neuroendocrine tumours--analysis of own material--a nine--year retrospective study. Hepatogastroenterology; 2010 Mar-Apr;57(98):236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to present the author's observations of the histological tumor types, occurrence and its surgical treatment.
  • Ultrasonography, scintigraphy, computed tomography or magnetic resonance imaging of abdominal cavity, pelvis, thorax or neck--depend on the tumor localization--were done in every individual.
  • All cases were subjected to surgical procedure with an aim to resect the tumour completely.
  • RESULTS: In the present study were observed 6 cases of carcinoids localized in ileum, cecum and sigmoid colon, 1 case of gastrinoma in pancreatic head localization, 1 case of insulinoma localized in pancreatic tail, 1 case of vipoma localised in pancreatic head, 2 cases of nesidioblastoma and 1 case of microcystic adenoma with neuroendocrine differentiation in pancreatic tail localization and 1 case of nonspecific apudoma observed in ileum.
  • In adrenal glands we observed 10 benign and 1 malignant pheochromocytoma (one bilateral female case with Multiple Endocrine Neoplasia type 2A).
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Neuroendocrine Tumors / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583420.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


33. Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P: Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch; 2007 Aug;451 Suppl 1:S9-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.
  • The gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are composed of cells with a neuroendocrine phenotype.
  • Well-differentiated tumors, well-differentiated carcinomas, poorly differentiated carcinomas, functioning tumors (with a hormonal syndrome), and nonfunctioning tumors are identified.
  • To predict their clinical behavior, these neuroendocrine tumors are classified on the basis of their clinicopathological features, including size, local invasion, angioinvasion, proliferative activity, histological differentiation, and metastases, into neoplasms with benign, uncertain, low-grade malignant and high-grade malignant behavior.
  • In addition, a tumor/nodes/metastases classification and a grading system are presented.
  • [MeSH-major] Digestive System Neoplasms / classification. Digestive System Neoplasms / pathology. Neuroendocrine Tumors / classification. Neuroendocrine Tumors / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1984 Dec;8(12):917-24 [6097131.001]
  • [Cites] Surgery. 1986 Jun;99(6):671-8 [2424108.001]
  • [Cites] Am J Surg. 1980 May;139(5):682-90 [6258453.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Am J Surg. 1964 Aug;108:132-41 [14195205.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Surgery. 1992 Apr;111(4):466-71 [1557693.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):517-22 [11914632.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1329-34 [1678681.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Lancet. 1977 Mar 26;1(8013):666-8 [66472.001]
  • [Cites] Medicine (Baltimore). 1949 Dec;28(4):427-47 [15399004.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):605-10 [12734754.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):811-7 [12766586.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):394-8 [16418841.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):185-90 [6258500.001]
  • [Cites] Hum Pathol. 1985 Jul;16(7):746-51 [3891579.001]
  • [Cites] Regul Pept. 1987 Jan;17(1):9-29 [2882565.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1075-82 [9298884.001]
  • [Cites] Gastroenterol Clin North Am. 1989 Dec;18(4):671-93 [2575601.001]
  • [Cites] Endocr Pathol. 1995 Autumn;6(3):229-237 [12114744.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;408(5):475-89 [2869609.001]
  • [Cites] Yale J Biol Med. 1996 Jan-Feb;69(1):69-74 [9041691.001]
  • [Cites] Hum Pathol. 1979 May;10(3):350-3 [89070.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1581-7 [17122515.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;388(1):51-67 [6258288.001]
  • [Cites] Neuroendocrinology. 2005;81(6):400-4 [16276118.001]
  • [Cites] Gastroenterology. 1968 Dec;55(6):677-86 [4302500.001]
  • [Cites] Br J Surg. 1993 Apr;80(4):502-4 [8495322.001]
  • [Cites] Virchows Arch. 2007 Aug;451 Suppl 1:S39-46 [17684763.001]
  • [Cites] Am J Pathol. 1984 Nov;117(2):167-70 [6093542.001]
  • [Cites] Surg Today. 1997;27(2):112-9 [9017986.001]
  • [Cites] Ann Surg. 1979 Jun;189(6):677-82 [222222.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):248-54 [15517368.001]
  • [Cites] N Engl J Med. 1986 Jul 31;315(5):287-91 [3014338.001]
  • [Cites] J Clin Gastroenterol. 2001 Aug;33(2):154-6 [11468445.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1233-9 [15316325.001]
  • [Cites] Ann Surg. 1981 Dec;194(6):692-7 [7030236.001]
  • [Cites] N Engl J Med. 1999 Aug 26;341(9):635-44 [10460814.001]
  • [Cites] Ann Surg. 1989 Apr;209(4):396-404 [2930285.001]
  • [Cites] Am J Clin Pathol. 1989 Jan;91(1):52-6 [2462784.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1975;365(4):275-88 [46649.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):952-5 [10970700.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2204-10 [11596039.001]
  • [Cites] Mayo Clin Proc. 1974 Jan;49(1):44-51 [4149030.001]
  • [Cites] J Pediatr Surg. 2002 Jun;37(6):887-92 [12037756.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1476-81 [9118026.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;405(3):311-23 [2579503.001]
  • [Cites] Scand J Gastroenterol. 1980;15(2):129-35 [6247758.001]
  • [Cites] Cancer. 1971 Oct;28(4):990-8 [4106849.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):588-94 [15832081.001]
  • [Cites] Ann Surg. 1986 Oct;204(4):468-79 [3532971.001]
  • [Cites] Digestion. 1999 Sep-Oct;60(5):428-39 [10473967.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):293-301 [14739487.001]
  • [Cites] Ann Surg. 1983 May;197(5):594-607 [6847279.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2029-37 [6271390.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):175-80 [8119718.001]
  • [Cites] Mayo Clin Proc. 1990 Nov;65(11):1399-407 [1700240.001]
  • [Cites] Dig Dis Sci. 1991 Jul;36(7):933-42 [2070707.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Dec;17(4):379-88 [10089055.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2540-5 [2655873.001]
  • [Cites] Am J Gastroenterol. 1981 Aug;76(2):125-31 [6272569.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):963-5 [14645360.001]
  • [Cites] J Pediatr Surg. 1985 Dec;20(6):734-6 [3003324.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):560-74 [16699310.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):706-11 [14608896.001]
  • [Cites] Cancer. 1979 Nov;44(5):1853-9 [227580.001]
  • [Cites] Am J Surg. 1985 Jun;149(6):775-9 [2409828.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1531-6 [17122508.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1860-74 [6627205.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1587-95 [15742328.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):25-31 [6691547.001]
  • [Cites] N Engl J Med. 1979 Aug 9;301(6):285-92 [377080.001]
  • [Cites] Gut. 2007 May;56(5):637-44 [17135306.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):43-50 [17270665.001]
  • [Cites] Mol Endocrinol. 1989 Oct;3(10):1589-95 [2691879.001]
  • [Cites] Mayo Clin Proc. 1976 Jul;51(7):417-29 [180358.001]
  • [Cites] J Surg Oncol. 1991 Mar;46(3):174-7 [1849211.001]
  • [Cites] Am J Surg Pathol. 1977 Sep;1(3):207-16 [920868.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):772-8 [3026608.001]
  • [Cites] World J Surg. 1993 Jul-Aug;17(4):481-8 [8103250.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2894-9 [8199985.001]
  • [Cites] Am J Surg Pathol. 1984 Aug;8(8):607-14 [6205601.001]
  • [Cites] Am J Surg. 1979 Jan;137(1):142-8 [215044.001]
  • [Cites] Mayo Clin Proc. 1991 Jul;66(7):711-9 [1677058.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):315-21 [1847579.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2097-108 [6435852.001]
  • [Cites] Scand J Gastroenterol Suppl. 1979;53:79-91 [290036.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1086-93 [9070484.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Am J Surg. 1983 Jul;146(1):124-32 [6869670.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):263-81 [2820062.001]
  • [Cites] Virchows Arch. 2000 Mar;436(3):217-23 [10782879.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):969-75 [15958864.001]
  • [Cites] Dis Colon Rectum. 1972 Sep-Oct;15(5):383-91 [4561188.001]
  • [Cites] Digestion. 1995;56(6):455-62 [8536814.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):8-18 [1531004.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):776-81 [11787850.001]
  • [Cites] Pathol Res Pract. 1992 Aug;188(6):751-6 [1437839.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Gut. 2002 Aug;51(2):184-90 [12117877.001]
  • [Cites] Ann Surg. 1955 Oct;142(4):709-23; discussion, 724-8 [13259432.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Jun;56(6):1236-42 [6132927.001]
  • [Cites] Mayo Clin Proc. 1978 Jan;53(1):19-23 [625140.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] J Clin Pathol. 2001 Nov;54(11):880-2 [11684726.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):223-31 [9665483.001]
  • [Cites] Gastroenterology. 1985 Mar;88(3):798-803 [2981755.001]
  • [Cites] Am J Gastroenterol. 1986 Jan;81(1):33-7 [2867674.001]
  • [Cites] Am J Clin Pathol. 1987 Aug;88(2):153-61 [2887104.001]
  • [Cites] Arch Pathol Lab Med. 1990 Jul;114(7):700-4 [1694655.001]
  • [Cites] Pathol Res Pract. 1988 Apr;183(2):155-68 [2898775.001]
  • [Cites] Ann Surg. 1990 Jan;211(1):9-14 [2294850.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):327-333 [12114794.001]
  • [Cites] Histopathology. 1992 Sep;21(3):215-23 [1356906.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1637-49 [7768367.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):183-5 [8459042.001]
  • [Cites] World J Gastroenterol. 2006 Sep 14;12(34):5440-6 [17006979.001]
  • [Cites] Am J Surg Pathol. 1986 May;10(5):348-57 [2422964.001]
  • [Cites] Am J Surg. 1980 Jul;140(1):119-25 [6249135.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2264-71 [16258711.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):251-5 [9500228.001]
  • [Cites] Surgery. 1974 Apr;75(4):597-609 [4366135.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1551-8 [14657715.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] Med Pediatr Oncol. 2002 Jan;38(1):65-6 [11835243.001]
  • [Cites] N Engl J Med. 1990 Mar 15;322(11):723-7 [1968616.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):135-40 [2293859.001]
  • [Cites] Gastroenterology. 1993 Apr;104(4):994-1006 [7681798.001]
  • [Cites] Lancet. 1963 Feb 2;1(7275):238-9 [14000847.001]
  • [Cites] Diabetes. 1979 Oct;28(10):925-36 [383556.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2320-2 [8402445.001]
  • [Cites] Br J Surg. 1979 Jun;66(6):373-8 [223712.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):139-48 [9700573.001]
  • [Cites] Postgrad Med J. 1995 Aug;71(838):485-6 [7567757.001]
  • [Cites] Histopathology. 1986 Feb;10(2):119-33 [3007321.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):752-60 [11395552.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1677-82 [18059224.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):499-506 [17033797.001]
  • [Cites] Virchows Arch. 2007 Aug;451 Suppl 1:S29-38 [17684762.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):773-81 [9287968.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Apr;52(4):820-2 [7204545.001]
  • [Cites] World J Surg. 1996 Feb;20(2):183-8 [8661815.001]
  • [Cites] Am J Clin Pathol. 1989 Jul;92(1):1-9 [2750701.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;392(3):263-9 [6115499.001]
  • (PMID = 17684761.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 176
  •  go-up   go-down


34. Cervantes-Solís C, Jiménez-González A, Zamora-Nava LE, Torre-Delgadillo A: [Thickening of the colon and terminal ileum documented with computer tomography and its correlation with colonoscopic findings at a third-level hospital]. Rev Gastroenterol Mex; 2010;75(2):158-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thickening of the colon and terminal ileum documented with computer tomography and its correlation with colonoscopic findings at a third-level hospital].
  • [Transliterated title] Engrosamiento colónico y de íleon terminal documentado por tomografía computarizada y su correlación con hallazgos colonoscópicos en un hospital de tercer nivel.
  • BACKGROUND: Tomographic finding of thickening of colon and terminal ileum and its correlation with colonoscopic findings has been poorly studied.
  • Various radiographic patterns of intestinal thickening suggestive of benign disease have been described, but they cannot completely rule out malignancy.
  • OBJECTIVE: To determine if a relationship exists between colonic wall or terminal ileum thickening documented by computed tomography with abnormal colonoscopic findings and colon cancer.
  • METHODS: Retrospective study of radiology database of a tertiary hospital identifying patients with report of thickening of terminal ileum or colon and have colonoscopy performed.
  • The main site of colonic thickening on CT was sigmoid in 8 (33.3%) cases.
  • The most common colonoscopic finding was colorectal tumor probably malignant in 7 (29.2%) patients, but adenocarcinoma was reported in 8 (33.3%) patients.
  • There was a statistically significant relationship between colonic thickening and colorectal cancer (p < 0.001) but no statistically significant association was found between thickening and sigmoid colon cancer.
  • CONCLUSIONS: The finding of thickening of colon documented by computed tomography is significantly associated with the presence of colorectal carcinoma.
  • [MeSH-major] Colon / pathology. Colon / radiography. Colonic Neoplasms / diagnosis. Colonoscopy. Ileum / pathology. Ileum / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20615783.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


35. Kim JJ, Song KY, Chin HM, Kim W, Jeon HM, Park CH, Park SM: Totally laparoscopic gastrectomy with various types of intracorporeal anastomosis using laparoscopic linear staplers: preliminary experience. Surg Endosc; 2008 Feb;22(2):436-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The reasons that gastrectomy was performed were adenocarcinoma in 41 cases, benign disease in three cases and gastrointestinal stromal tumor in one case, and the types of surgery were distal gastrectomy (40), total gastrectomy (four) and pylorus-preserving gastrectomy (one).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2005 Jul 1;91(1):26-32 [15999355.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1172-6 [16132323.001]
  • [Cites] Am J Surg. 1995 Oct;170(4):381-6 [7573733.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):37-40 [11036137.001]
  • [Cites] Surg Endosc. 2005 Oct;19(10 ):1353-7 [16021369.001]
  • [Cites] Dis Colon Rectum. 1983 Sep;26(9):586-9 [6347569.001]
  • [Cites] J Surg Oncol. 2005 Jul 1;91(1):90-4 [15999352.001]
  • [Cites] Gastric Cancer. 2002;5(1):1-5 [12021853.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):650-2 [9171126.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):284-7 [12168979.001]
  • [Cites] Surg Endosc. 2005 Feb;19(2):168-73 [15580441.001]
  • [Cites] Surg Endosc. 1992 May-Jun;6(3):160 [1386948.001]
  • [Cites] Surgery. 2005 Mar;137(3):317-22 [15746786.001]
  • [Cites] Am J Surg. 2002 Jul;184(1):58-60 [12135722.001]
  • [Cites] J Am Coll Surg. 1998 Jan;186(1):100-3 [9449605.001]
  • [Cites] Surg Endosc. 2005 Dec;19(12):1592-6 [16247578.001]
  • [Cites] Surg Endosc. 2003 May;17(5):758-62 [12618942.001]
  • (PMID = 17593437.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Beddy D, Mulsow J, Watson RW, Fitzpatrick JM, O'Connell PR: Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg; 2006 Oct;93(10):1290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease.
  • Stricturing that occurs in patients with Crohn's disease after treatment with anti-tumour necrosis factor (TNF) alpha may be due to dysregulation of CTGF homeostasis.
  • METHODS: Fibroblasts were isolated by a primary explant technique from serosal biopsies of strictured segments of bowel in eight patients undergoing resection for Crohn's disease and from normal colon in seven patients having resection for benign or malignant colorectal disease.
  • [MeSH-major] Crohn Disease / metabolism. Fibroblasts / drug effects. Immediate-Early Proteins / drug effects. Transforming Growth Factor beta / pharmacology. Tumor Necrosis Factor-alpha / pharmacology

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838391.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTGF protein, human; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; 139568-91-5 / Connective Tissue Growth Factor
  •  go-up   go-down


37. Nagy A, Kovacs T, Lóderer Z: Experiences with PPH gun stapled ileo or coloanal anastomoses after ultralow rectal resections and proctocolectomies with J pouch reconstructions. Acta Chir Iugosl; 2006;53(2):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On 47 totalcolectomised FAP and UC patients and 9 low rectal benign or clinically T1 or T2N0 rectal tumor resection there was only 5 radiologically proven anastomotic leakadge without serious septic complications.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Ileum / surgery. Proctocolectomy, Restorative. Rectum / surgery. Surgical Stapling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139887.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


38. Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V, Burstein DE: Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol; 2005 Dec;18(12):1618-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed an immunocytochemical survey of XIAP expression in cell blocks from benign and malignant body cavity effusions and washes.
  • The prevalence of staining for specific malignancies varied with the tissue of origin as follows: ovarian (13/13, 100%); lung (9/11, 82%), breast (6/13, 46%); gastric (4/7, 57%), colon (0/4, 0%), pancreas (2/3, 67%), gallbladder (1/1, 100%), fallopian tube (1/3, 33%), endometrial (6/7, 86%), mesothelioma (4/5, 80%), carcinoma of unknown primary (5/5, 100%) and hematopoietic malignancies (3/9, 33%).
  • Benign effusions (n = 35) were virtually XIAP-negative except for two cases (6%) in which histiocytes showed moderate staining.
  • XIAP immunostaining, when strong, allows for ready distinction of malignant from benign and reactive cell populations.
  • The degree of XIAP staining of tumor cells may be a means of identifying the most therapy-resistant cases (ie, those with strong XIAP expression), and allow additional triaging to XIAP-blocking drugs presently being developed and clinically tested.
  • [MeSH-major] Ascitic Fluid / chemistry. Biomarkers, Tumor / analysis. Immunoenzyme Techniques / methods. Peritoneal Lavage. Pleural Effusion, Malignant / chemistry. X-Linked Inhibitor of Apoptosis Protein / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118627.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / X-Linked Inhibitor of Apoptosis Protein
  •  go-up   go-down


39. Zhai QJ, Ozcan A, Hamilton C, Shen SS, Coffey D, Krishnan B, Truong LD: PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol; 2010 Jul;18(4):323-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although PAX-2 is shown to be a sensitive marker for tumors derived from these organs, but whether it is specific, that is, whether other tumor types also express PAX-2, has not been systematically evaluated in either primary or metastatic tumors.
  • Among the primary neoplasms, PAX-2 was noted in 104/122 (85%) of renal cell carcinoma, 31/95 carcinomas of Müllerian origin, 17/17 (100%) lymphomas, 4/4 (100%) nephrogenic adenomas, and 1/16 (6%) benign parathyroid tumors, but was negative in 477 other tumors.
  • Among the metastatic tumors, PAX-2 was noted in 70/95 (74%) metastatic renal cell carcinomas, 14/20 (70%) metastatic tumors of Müllerian origin, 1/20 (5%) metastatic colon carcinoma of lymph nodes, 1/62 (2%) metastatic breast carcinoma of lymph nodes, but was not seen in the remaining 247 metastatic tumors.
  • PAX-2 is a sensitive and specific marker for tumors of renal or Müllerian origin in both primary and metastatic contexts.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216401.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor
  •  go-up   go-down


40. Gao B, Sun Y, Liu Z, Meng F, Shi B, Liu Y, Xu Z: A logistic regression model for predicting malignant pheochromocytomas. J Cancer Res Clin Oncol; 2008 Jun;134(6):631-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all 130 cases with malignant or benign PCCs, 15 predictive variables were observed and entered in the logistic regression analysis in a backward stepwise way.
  • High cellularity had the highest odds ratio (OR), followed by spindle cell (>10% of tumor volume), atypical mitotic figure, periadrenal adipose tissue invasion, mitotic figures [>3/10 high-power field (HPF)], cellular monotony, capsular invasion, vascular invasion, and central or confluent tumor necrosis.
  • High cellularity, spindle cell (>10% of tumor volume) and atypical mitotic figure were selected to built a logistic model.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Braz J Med Biol Res. 2000 Oct;33(10):1177-89 [11004718.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1409-10 [15371856.001]
  • [Cites] Stat Med. 2004 Aug 30;23(16):2567-86 [15287085.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5615-9 [11701743.001]
  • [Cites] Hinyokika Kiyo. 2005 Apr;51(4):291-6 [15912793.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):611-20 [17297554.001]
  • [Cites] Br J Surg. 1979 Jul;66(7):456-65 [466037.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:533-40 [17102122.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):364-72 [15671347.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1235-46 [12368197.001]
  • [Cites] Surg Gynecol Obstet. 1982 Jun;154(6):801-18 [7079921.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:541-56 [17102123.001]
  • [Cites] Obstet Gynecol. 2000 Jul;96(1):75-80 [10862846.001]
  • [Cites] J Surg Res. 2005 Oct;128(2):199-206 [16140341.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2231-5 [11344232.001]
  • [Cites] J Clin Epidemiol. 2005 May;58(5):475-83 [15845334.001]
  • [Cites] Cancer. 1977 Nov;40(5):1987-2004 [922654.001]
  • [Cites] Neurol Res. 2005 Oct;27(7):747-54 [16197812.001]
  • (PMID = 17999082.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Hobson KG, Ghaemmaghami V, Roe JP, Goodnight JE, Khatri VP: Tumors of the retrorectal space. Dis Colon Rectum; 2005 Oct;48(10):1964-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the retrorectal space.
  • PURPOSE: Retrorectal tumors are a diverse group of masses derived from a variety of embryologic origins.
  • Benign and malignant lesions behave similarly.
  • Biopsy of these lesions should be avoided to prevent tumor seeding, fecal fistula, meningitis, and abscess formation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981068.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


42. Terzi C, Unek T, Sağol O, Yilmaz T, Füzün M, Sökmen S, Ergör G, Küpelioğlu A: Is rectal washout necessary in anterior resection for rectal cancer? A prospective clinical study. World J Surg; 2006 Feb;30(2):233-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Implantation of exfoliated malignant cells has been suggested as a possible mechanism of tumor recurrence in colorectal anastomoses that might be prevented by cytocidal washout.
  • METHODS: Between May 1999 and March 2004, 96 patients with carcinoma of the rectum and distal sigmoid colon undergoing anterior resection under the care of three surgeons (only one of whom routinely performed rectal washout) were prospectively studied.
  • The fluid was then classified as "acellular," "malignant cells identified," or "benign cells identified" by pathologists.
  • [MeSH-major] Colectomy / methods. Neoplasm Recurrence, Local / prevention & control. Neoplasm Seeding. Peritoneal Lavage / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Female. Follow-Up Studies. Humans. Intraoperative Care / methods. Male. Middle Aged. Neoplasm Staging. Probability. Prospective Studies. Reference Values. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Dec 1;52(11):1986-92 [6354419.001]
  • [Cites] Aust N Z J Surg. 1965 Feb;34:178-87 [14271060.001]
  • [Cites] Ann R Coll Surg Engl. 1979 Jul;61(4):251-7 [382965.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):602 [4027530.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1050-2 [7648150.001]
  • [Cites] Ann R Coll Surg Engl. 1989 Jan;71(1):54-6 [2923422.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):411-23 [15875292.001]
  • [Cites] Br J Surg. 1987 Nov;74(11):1049-52 [3690235.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):800-11 [9637543.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Surg Gynecol Obstet. 1988 Apr;166(4):357 [3353834.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1710-2 [11156455.001]
  • [Cites] Dis Colon Rectum. 1985 Mar;28(3):164-7 [3971822.001]
  • [Cites] Acta Chir Belg. 1994 Sep-Oct;94(5):258-62 [7976066.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):389-402 [12626917.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):664-5 [6478153.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):206-7 [11856135.001]
  • [Cites] Dis Colon Rectum. 1985 Apr;28(4):260-1 [3979229.001]
  • [Cites] Dis Colon Rectum. 1992 Mar;35(3):238-41 [1740068.001]
  • [Cites] Br J Surg. 1989 Apr;76(4):331-4 [2541860.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):291-6 [14991490.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1127-33 [9749496.001]
  • [Cites] Surg Today. 1997;27(5):457-9 [9130352.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Ann Med. 1997 Apr;29(2):91-3 [9187224.001]
  • [Cites] Dis Colon Rectum. 1998 Nov;41(11):1432-4 [9823812.001]
  • [Cites] Br J Surg. 1984 Feb;71(2):98-100 [6692125.001]
  • [Cites] Br J Surg. 1982 May;69(5):275-6 [7074339.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • (PMID = 16425079.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Shen P, Geisinger KR, Zagoria R, Levine EA: Pathologic correlation study of microwave coagulation therapy for hepatic malignancies using a three-ring probe. J Gastrointest Surg; 2007 May;11(5):603-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo pathologic evaluation of ablated tumor tissue is not well described for the three-ring microwave probe.
  • Gross and histologic evaluations of the tumor were performed, including nicotinamide adenine dinucleotide (NADH) vital staining.
  • A total of nine patients with metastatic colon cancer were enrolled and had NADH stains performed of their pathologic specimens.
  • Fifty-six percent of the tumors demonstrated evidence of spontaneous coagulative necrosis on immediate histologic examination.
  • NADH vital staining was performed of the ablation zones with 100% absence of staining in the tumor tissue and in benign hepatic parenchyma, which is consistent with irreversible cellular damage.
  • In conclusion, in vivo MCT of hepatic malignancies with the three-ring probe produces nonviable tumor cells after a 5-min ablation.
  • [MeSH-minor] Carcinoma / pathology. Carcinoma / secondary. Carcinoma / surgery. Cell Death. Colonic Neoplasms / pathology. Coloring Agents. Equipment Design. Hepatectomy / methods. Humans. NAD / analysis. Necrosis. Prospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):592-8 [11180892.001]
  • [Cites] Radiology. 2005 Jul;236(1):132-9 [15987969.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):912-20 [10679662.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jan;178(1):47-51 [11756085.001]
  • [Cites] Surg Endosc. 2004 Mar;18(3):390-6 [14735342.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Apr;5(2):337-52 [9019355.001]
  • [Cites] Hepatogastroenterology. 1999 Sep-Oct;46(29):2894-900 [10576369.001]
  • [Cites] Radiology. 2004 Apr;231(1):143-9 [14990816.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):657-62; discussion 662-4 [10843361.001]
  • [Cites] Ann Surg. 1989 Aug;210(2):127-38 [2667471.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1354-60 [16332494.001]
  • [Cites] Endoscopy. 2000 Aug;32(8):591-7 [10935786.001]
  • [Cites] AJR Am J Roentgenol. 2006 Oct;187(4):W333-40 [16985103.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2452-63 [10861420.001]
  • [Cites] J Urol. 2002 Dec;168(6):2401-5 [12441926.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):275-83 [12679313.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):274-6 [8472130.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):52-8 [12513961.001]
  • [Cites] Br J Surg. 2003 Jan;90(1):122 [12520590.001]
  • (PMID = 17393259.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0U46U6E8UK / NAD
  •  go-up   go-down


44. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, some studies have suggested that SIRT1 could be over-expressed in breast, prostate and colon cancers and up-regulated SIRT1 inactivates p53 by deacetylation.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


45. Okubo H, Ozeki K, Tanaka T, Matsuo T, Mochinaga N: Primary malignant fibrous histiocytoma of the ascending colon: report of a case. Surg Today; 2005;35(4):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant fibrous histiocytoma of the ascending colon: report of a case.
  • We report a rare case of primary malignant fibrous histiocytoma (MFH) of the ascending colon.
  • A 66-year-old man presented to our hospital with epigastralgia, and abdominal ultrasonography and computed tomography showed a large soft-tissue mass in the ascending colon.
  • Barium enema and endoscopic examination showed a huge tumor in the ascending colon.
  • At laparotomy, we found a tumor in the ascending colon and performed a right hemicolectomy with en bloc lymph node dissection.
  • The resected specimen contained a tumor measuring 14.5 x 8.0 x 4.5 cm, the cut surface of which was yellowish.
  • Based on histological and immunohistological studies, the tumor was diagnosed as MFH of the ascending colon.
  • [MeSH-major] Colon, Ascending. Colonic Neoplasms / surgery. Histiocytoma, Benign Fibrous / surgery

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15815852.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Shantha Kumara HM, Hoffman A, Kim IY, Feingold D, Dujovny N, Kalady M, Luchtefeld M, Whelan RL: Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels. Surg Endosc; 2009 Feb;23(2):409-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels.
  • INTRODUCTION: Plasma vascular endothelial growth factor (VEGF) levels are increased after surgery and may stimulate tumor growth after cancer resection.
  • This study's purpose was to determine the impact of open and minimally invasive (MIS) colorectal resection (CR) for benign indications on plasma Ang 1 and 2 levels.
  • CONCLUSION: CR for benign pathology results in higher Ang 2 levels, lower Ang 1 levels, and lower Ang 1 to Ang 2 ratios early after surgery.
  • These results, plus the already noted VEGF increases, suggest that surgery results in proangiogenic plasma protein changes that may stimulate tumor growth early after surgery.
  • [MeSH-major] Angiopoietin-1 / blood. Angiopoietin-2 / blood. Colectomy. Colonic Diseases / surgery. Laparoscopy. Rectal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Surg Endosc. 2009 Feb;23(2):416. Kallady, M [corrected to Kalady, M]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):55-9 [15531967.001]
  • [Cites] J Pathol. 2004 Sep;204(1):1-10 [15307132.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):213-23 [10068209.001]
  • [Cites] Cardiovasc Res. 2001 Feb 16;49(3):659-70 [11166279.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jan;385(1):2-9 [10664112.001]
  • [Cites] World J Surg. 1996 May;20(4):460-4 [8662135.001]
  • [Cites] J Lab Clin Med. 2005 Apr;145(4):194-203 [15962838.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):510 [9181567.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [Cites] Science. 1998 Oct 16;282(5388):468-71 [9774272.001]
  • [Cites] Biochem Pharmacol. 2001 Feb 1;61(3):253-70 [11172729.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1670-4 [15540297.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):361-73 [11310829.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • (PMID = 18813991.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2
  •  go-up   go-down


47. Shiroshita H, Komori Y, Tajima M, Bandoh T, Arita T, Shiraishi N, Kitano S: Laparoscopic examination and resection for giant lipoma of the omentum: a case report and review of related literature. Surg Laparosc Endosc Percutan Tech; 2009 Oct;19(5):e217-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 71-year-old male patient was admitted with a diagnosis of sigmoid colon cancer.
  • Laparoscopic examination revealed a smooth-surfaced, giant yellow tumor at the lower border of the greater omentum that was unattached to the surrounding organs.
  • After laparoscopic resection of the tumor and cholecystectomy, a 10-cm midline incision was made in the lower abdomen to remove the tumor and the gallbladder.
  • We then performed a sigmoidectomy for sigmoid colon cancer through the same laparotomy.
  • The resected tumor measured 29 x 19 x 3 cm and weighed 1250 g, and a histopathologic examination revealed a benign lipoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851258.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


48. Tedesco MM, Curet MJ: Laparoscopic-assisted colectomy for colon cancer. Expert Rev Med Devices; 2006 Jul;3(4):415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic-assisted colectomy for colon cancer.
  • Laparoscopic-assisted colectomy (LAC) for colon cancer was first described in 1991.
  • Unlike other laparoscopic procedures used to treat benign disease, the LAC for colon cancer has been slow to gain acceptance for a variety of reasons.
  • Recently, several large, randomized controlled trials have demonstrated that LACs are comparable with open colectomies with respect to oncological issues such as survival, port-site metastases and tumor recurrence.
  • Moreover, there are significant patient benefits with the use of LAC including duration of analgesic use, return of bowel function, length of stay and return to normal activity.
  • [MeSH-major] Colectomy. Colonic Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Humans. Length of Stay. Neoplasm Recurrence, Local. Quality of Life. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866638.001).
  • [ISSN] 1743-4440
  • [Journal-full-title] Expert review of medical devices
  • [ISO-abbreviation] Expert Rev Med Devices
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


49. Machado-Aranda D, Malamet M, Chang YJ, Jacobs MJ, Ferguson L, Silapaswan S, Goriel Y, Kolachalam R, Mittal VK: Prevalence and management of gastrointestinal stromal tumors. Am Surg; 2009 Jan;75(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and management of gastrointestinal stromal tumors.
  • The prevalence and characteristics of patients with confirmed gastrointestinal stromal tumor (GIST) in a community hospital over a 6-year period are described.
  • Our objective was to communicate our experience managing this rare tumor of the gastrointestinal tract.
  • Patients with a diagnosis of GIST, cells of Cajal tumor, and/or different varieties of gastrointestinal sarcoma were included in this study.
  • These tumors had to have a positive C-kit on immunohistochemistry.
  • The most common clinical presentation was an intra-abdominal nonobstructing mass followed by an endoscopically detected mass or incidental tumors found during unrelated surgery.
  • Over half of these tumors were located in the stomach.
  • Other sites were the small intestine, colon, esophagus, and rectal-vaginal septum.
  • Only 18 per cent of these tumors were considered benign, whereas 35 per cent were considered to have some malignant potential and 47 per cent were of undetermined potential.
  • In surgically resected tumors, we found a 42 per cent recurrence rate with a median average time of recurrence of 22 months.
  • [MeSH-major] Gastrointestinal Stromal Tumors / epidemiology. Gastrointestinal Stromal Tumors / surgery. Hospitals, Community

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213398.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


50. Amato A: Colorectal gastrointestinal stromal tumor. Tech Coloproctol; 2010 Nov;14 Suppl 1:S91-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal gastrointestinal stromal tumor.
  • Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm arising in the digestive tract, with an estimated prevalence of 15-20 per 1,000,000.
  • Benign GISTs are more common, but many tumors are of uncertain malignant potential; tumor size and rate of mitosis are still the most reliable criteria for assessing the risk of an aggressive behavior.
  • Segmental colectomy with negative margins is recommended, and local excision is oncologically adequate in highly selected rectal tumors.
  • [MeSH-major] Colorectal Neoplasms. Gastrointestinal Stromal Tumors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S37-8 [12528771.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):89-96 [17145623.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):981-2 [16583196.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1098-103 [15522557.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Dis Colon Rectum. 2006 May;49(5):609-15 [16552495.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):14-24 [17072676.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S60-5 [12528774.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):526-32 [17139461.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1316-9 [15793646.001]
  • [Cites] J Surg Oncol. 2009 Jan 1;99(1):42-7 [18942073.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):109-14 [16639561.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1091-5 [11021812.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):625-41 [12717247.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Feb;18(2):147-51 [12542597.001]
  • [Cites] Am J Surg. 2006 Jan;191(1):121-3 [16399120.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2325-31 [16710031.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):585-93 [17646785.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):728-34 [9720500.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1922-9 [15622586.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3282-90 [15161681.001]
  • [Cites] Surg Today. 2007;37(6):455-9 [17522761.001]
  • [Cites] Surg Today. 2007;37(8):698-701 [17643218.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):66-74 [10618607.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):791-5 [10702394.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):332-9 [12594669.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14 ):2012-20 [12957455.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8118-21 [11719439.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):53-60 [9916918.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Scand J Surg. 2003;92(3):195-9 [14582540.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1339-52 [11023095.001]
  • [Cites] Colorectal Dis. 2008 Nov;10 (9):951-2 [18294266.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7 [12528778.001]
  • (PMID = 20967481.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


51. Shantha Kumara HM, Cabot JC, Hoffman A, Luchtefeld M, Kalady MF, Hyman N, Feingold D, Baxter R, Whelan RL: Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period. Surg Endosc; 2009 Apr;23(4):694-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period.
  • VEGF induces wound and tumor angiogenesis by binding to endothelial cell (EC)-bound VEGF-receptor 1 (VEGFR1) and VEGFR2.
  • The importance of the MICR-related VEGF changes depends on the effect of surgical procedures on sVEGFR1 and sVEGFR2; this study assessed levels of these proteins after MICR for benign indications.
  • [MeSH-major] Colectomy / methods. Colonic Diseases / surgery. Minimally Invasive Surgical Procedures / methods. Vascular Endothelial Growth Factor Receptor-1 / blood. Vascular Endothelial Growth Factor Receptor-2 / blood

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):44-50 [7615975.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] J Vasc Surg. 1998 Sep;28(3):535-40 [9737465.001]
  • [Cites] Am J Cardiol. 1999 Feb 1;83(3):337-9 [10072219.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):405-10 [17214745.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):490-8 [10667605.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):14-8 [11857378.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Sci STKE. 2001 Dec 11;2001(112):re21 [11741095.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):608-13 [16891801.001]
  • [Cites] Crit Care Med. 2008 Apr;36(4):1284-9 [18379256.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):617-23 [11274009.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3824-30 [10339489.001]
  • [Cites] Shock. 2008 Apr;29(4):452-7 [18598002.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Circ Res. 2001 Feb 2;88(2):167-74 [11157668.001]
  • [Cites] Clin Sci (Lond). 1997 May;92(5):453-4 [9176017.001]
  • [Cites] Surg Endosc. 2009 Feb;23(2):409-15 [18813991.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1931-4 [11929804.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):331-5 [12653578.001]
  • [Cites] Eur Respir J. 2001 Jul;18(1):100-6 [11510779.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Cancer. 2004 May 1;100(9):1884-91 [15112269.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • [Cites] Clin Exp Immunol. 2000 Jan;119(1):182-8 [10606981.001]
  • [Cites] J Exp Med. 1992 Nov 1;176(5):1375-9 [1402682.001]
  • (PMID = 19184203.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


52. Torres A, Torres K, Paszkowski T, Staśkiewicz GJ, Maciejewski R: Cytokine response in the postoperative period after surgical treatment of benign adnexal masses: comparison between laparoscopy and laparotomy. Surg Endosc; 2007 Oct;21(10):1841-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine response in the postoperative period after surgical treatment of benign adnexal masses: comparison between laparoscopy and laparotomy.
  • The purpose of the present study was the comparative assessment in sera of patients with benign adnexal masses treated by laparoscopy or laparotomy of the following proinflammatory and anti-inflammatory cytokines: interleukin (IL)-1beta, IL-6, IL-8, tumor necrosis factor-alpha (TNF-alpha), and IL-10 in the early postoperative period.
  • METHODS: A total of 40 patients with benign adnexal masses were studied; 25 of whom underwent laparoscopy and 15, laparotomy.
  • RESULTS: Concentrations of IL-6 were significantly increased in both groups at 4 h, 24 h, and 48 h after the surgery; levels of IL-10 showed a significant increase 4 h and 24 h after the operation; an increase in IL-1beta levels was observed only after laparotomy; no significant variations were observed in serum levels of IL-8; the postoperative increase of IL-1beta, IL-6, and IL-10 levels was more pronounced in patients undergoing laparotomy than in those treated laparoscopically; length of the surgical procedure, amount of CO2 used, tumor diameter, age, and body mass index (BMI) of the patients did not influence the postoperative patterns of the studied cytokines.
  • CONCLUSIONS: Systemic cytokine response after operations for benign adnexal masses depends on the degree of the surgical trauma, and is less pronounced in patients undergoing laparoscopy.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mymensingh Med J. 2004 Jul;13(2):153-6 [15284691.001]
  • [Cites] Surg Endosc. 2002 Aug;16(8):1214-9 [12189483.001]
  • [Cites] Ann Clin Biochem. 1997 Sep;34 ( Pt 5):543-5 [9293310.001]
  • [Cites] J Surg Res. 2005 Jun 1;126(1):12-8 [15916969.001]
  • [Cites] Saudi Med J. 2002 Apr;23(4):436-40 [11953771.001]
  • [Cites] Int J Urol. 1996 Sep;3(5):340-2 [8886908.001]
  • [Cites] Maturitas. 1998 Sep 20;30(1):51-4 [9819783.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2690-4 [14669314.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jan;192(1):48-54 [15672002.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1595-9 [15532785.001]
  • [Cites] Acta Obstet Gynecol Scand. 1997 Jul;76(6):563-6 [9246964.001]
  • [Cites] Br J Surg. 1996 Mar;83(3):347-8 [8665188.001]
  • [Cites] Semin Laparosc Surg. 2004 Mar;11(1):37-44 [15094977.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):70-6 [10631365.001]
  • [Cites] Eur J Surg. 2000 Jul;166(7):540-4 [10965832.001]
  • [Cites] Acta Chir Hung. 1997;36(1-4):138-40 [9408318.001]
  • [Cites] Shock. 2000 Aug;14(2):91-4 [10947148.001]
  • [Cites] J Am Coll Surg. 1996 May;182(5):423-30 [8620278.001]
  • [Cites] Eur J Anaesthesiol. 2001 Aug;18(8):530-9 [11473560.001]
  • [Cites] Arch Surg. 2006 Nov;141(11):1132-40 [17116807.001]
  • [Cites] Anaesthesia. 1999 Aug;54(8):733-8 [10460524.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jan;385(1):2-9 [10664112.001]
  • [Cites] Surg Endosc. 2002 May;16(5):836-42 [11997833.001]
  • [Cites] Int J Urol. 2002 Jun;9(6):329-33 [12110097.001]
  • [Cites] Surg Endosc. 2004 Jul;18(7):1022-8 [15136930.001]
  • [Cites] J Invest Surg. 2000 May-Jun;13(3):161-7 [10933112.001]
  • [Cites] Dis Colon Rectum. 2003 Sep;46(9):1238-44 [12972969.001]
  • [Cites] Eur Urol. 2000 Mar;37(3):241-50 [10720847.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83(1):37-43 [14511870.001]
  • [Cites] J Immunol. 1991 Dec 1;147(11):3815-22 [1940369.001]
  • [Cites] JAMA. 1993 Apr 14;269(14):1829-35 [8459516.001]
  • [Cites] Am J Surg. 1999 Jan;177(1):55-60 [10037309.001]
  • [Cites] Surg Endosc. 2001 May;15(5):463-6 [11353962.001]
  • [Cites] Surg Endosc. 2003 Feb;17(2):242-6 [12399854.001]
  • [Cites] Acta Obstet Gynecol Scand. 2000 Oct;79(10):866-71 [11304971.001]
  • [Cites] J Am Coll Surg. 2002 May;194(5):557-66; discussion 566-7 [12022597.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):467-71 [9112894.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):638-46 [11357021.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):439-54 [15212338.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jul;177(1):109-14 [9240592.001]
  • [Cites] J Endocrinol Invest. 2004 Feb;27(2):106-10 [15129803.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1296-306 [11578282.001]
  • [Cites] J Clin Anesth. 1998 May;10(3):184-8 [9603586.001]
  • [Cites] Am J Surg. 2004 Mar;187(3):372-7 [15006565.001]
  • [Cites] Surg Endosc. 2006 Feb;20(2):316-21 [16247573.001]
  • [Cites] Obes Surg. 2002 Apr;12(2):276-9 [11975228.001]
  • [Cites] Eur Surg Res. 2000;32(5):261-6 [11111169.001]
  • [Cites] J Clin Anesth. 1997 Jun;9(4):293-8 [9195352.001]
  • [Cites] J Ultrasound Med. 1998 Jun;17 (6):369-72; quiz 373-4 [9623473.001]
  • [Cites] Surgery. 2006 Jan;139(1):39-45 [16364716.001]
  • [Cites] Br J Surg. 1992 Aug;79(8):757-60 [1393463.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):147-55 [12576886.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2000 Feb;10(1):35-40 [10706301.001]
  • [Cites] Surgery. 2000 Feb;127(2):117-26 [10686974.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):506-11 [10749610.001]
  • [Cites] J Korean Med Sci. 2005 Jun;20(3):468-72 [15953871.001]
  • [Cites] JAMA. 1994 Jan 19;271(3):226-33 [8080494.001]
  • [Cites] Surg Endosc. 2001 Nov;15(11):1289-93 [11727135.001]
  • [Cites] Surg Endosc. 1998 Dec;12(12):1381-5 [9822461.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):482-90; discussion 490-2 [7574928.001]
  • [Cites] Surg Endosc. 2002 Feb;16(2):313-6 [11967686.001]
  • [Cites] Shock. 2000 Aug;14(2):157-62 [10947160.001]
  • [Cites] Am J Surg. 1998 Apr;175(4):311-6 [9568659.001]
  • [Cites] BMJ. 1989 Dec 2;299(6712):1363-7 [2513964.001]
  • (PMID = 17356933.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


53. Namasivayam S, Martin DR, Saini S: Imaging of liver metastases: MRI. Cancer Imaging; 2007;7:2-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific characterization of liver metastases in patients with primary non-hepatic tumors is crucial to avoid unnecessary diagnostic work-up for incidental benign liver lesions.
  • MR contrast agents provide critical tumor characterization and can be safely used in patients with iodine contrast allergy and renal failure.
  • The degree and nature of tumor vascularity form the basis for liver lesion characterization based on enhancement properties.
  • Colon, lung, breast and gastric carcinomas are the most common tumors causing hypovascular liver metastases, and typically show perilesional enhancement.
  • Neuroendocrine tumors including carcinoid and islet cell tumors, renal cell carcinoma, breast, melanoma, and thyroid carcinoma are tumors most commonly causing hypervascular hepatic metastases, which may develop early enhancement with variable degrees of washout and peripheral rim enhancement.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1407-13 [7484575.001]
  • [Cites] Radiology. 1995 Aug;196(2):471-8 [7617863.001]
  • [Cites] Radiology. 1996 Mar;198(3):881-7 [8628887.001]
  • [Cites] Radiology. 1996 May;199(2):513-20 [8668804.001]
  • [Cites] Radiology. 1996 Jul;200(1):59-67 [8657946.001]
  • [Cites] Radiology. 1996 Sep;200(3):785-92 [8756932.001]
  • [Cites] J Magn Reson Imaging. 1996 Mar-Apr;6(2):291-4 [9132092.001]
  • [Cites] Eur Radiol. 1997;7(2):275-80 [9038130.001]
  • [Cites] Radiology. 1997 May;203(2):449-56 [9114103.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 2):626-30 [9245955.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 2):631-7 [9245956.001]
  • [Cites] Radiol Clin North Am. 1998 Mar;36(2):287-97 [9520982.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2005 May;13(2):241-54, v-vi [15935310.001]
  • [Cites] Radiol Clin North Am. 2005 Sep;43(5):861-86, viii [16098344.001]
  • [Cites] Cancer Imaging. 2005;5 Spec No A:S149-56 [16361131.001]
  • [Cites] AJR Am J Roentgenol. 2006 Apr;186(4):1051-8 [16554578.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • [Cites] Eur Radiol. 2006 Jun;16(6):1337-45 [16453115.001]
  • [Cites] Cancer Imaging. 2006;6:33-42 [16766267.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1898-905 [16691378.001]
  • [Cites] Radiology. 1999 Oct;213(1):86-91 [10540645.001]
  • [Cites] Radiology. 2000 Apr;215(1):89-94 [10751472.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2000 Nov;8(4):741-56 [11149677.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):73-90 [11933597.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):165-79, vii [11933587.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jul;151(1):79-84 [3259825.001]
  • [Cites] Radiology. 1992 Jan;182(1):167-74 [1309218.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jan-Feb;17(1):67-74 [8419443.001]
  • [Cites] Radiology. 1994 Dec;193(3):657-63 [7972804.001]
  • [Cites] Radiology. 1995 Dec;197(3):575-7 [7480718.001]
  • (PMID = 17293303.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC1804118
  •  go-up   go-down


54. Hornick JL, Bundock EA, Fletcher CD: Hybrid schwannoma/perineurioma: clinicopathologic analysis of 42 distinctive benign nerve sheath tumors. Am J Surg Pathol; 2009 Oct;33(10):1554-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid schwannoma/perineurioma: clinicopathologic analysis of 42 distinctive benign nerve sheath tumors.
  • Benign nerve sheath tumors include neurofibromas, schwannomas, and perineuriomas.
  • In recent years, nerve sheath tumors showing discrete areas of more than one histologic type have been described.
  • We have recently recognized tumors showing hybrid features of schwannoma and soft tissue perineurioma.
  • The tumors arose in a wide distribution: 19 lower limb, 12 upper limb, 6 head and neck, 4 trunk, and 1 colon.
  • Tumor size ranged from 0.7 to 17.5 cm (mean, 3 cm).
  • Most tumors involved superficial subcutis (11 also dermis); only 3 were intramuscular.
  • Histologically, the tumors were usually well circumscribed but unencapsulated, and composed of spindle cells with plump, tapering nuclei, and palely eosinophilic cytoplasm with indistinct cell borders, arranged in a storiform, whorled, and/or lamellar architecture.
  • Only 1 tumor showed infiltrative margins.
  • One tumor showed a plexiform growth pattern.
  • Six tumors showed focally myxoid stroma and 11 contained scattered cells with degenerative nuclear atypia.
  • Mitoses ranged from 0 to 4 per 30 high power fields; 32 tumors had no mitoses.
  • All tumors showed staining for S100 protein and EMA; 98% were positive for CD34, 84% for GFAP, and 80% for claudin-1.
  • Fourteen tumors contained rare neurofilament protein-positive axons.
  • Most tumors were composed of approximately 60% to 70% of Schwann cells and 30% to 40% of perineurial cells.
  • After a mean follow-up of 24 months (range, 6 to 60 mo), 1 tumor recurred locally, after incomplete excision.
  • Benign nerve sheath tumors showing predominantly schwannian cytomorphology and perineurioma-like architecture are composed of an admixture of both cell types.
  • These tumors usually arise in the dermis and subcutis and occur over a wide age range and anatomic distribution.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucin-1 / biosynthesis. S100 Proteins / biosynthesis. Young Adult

  • Genetic Alliance. consumer health - Schwannoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623031.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / S100 Proteins
  •  go-up   go-down


55. John R, El-Rouby NM, Tomasetto C, Rio MC, Karam SM: Expression of TFF3 during multistep colon carcinogenesis. Histol Histopathol; 2007 07;22(7):743-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TFF3 during multistep colon carcinogenesis.
  • The pathogenesis of colon cancer is not well understood.
  • This common type of cancer is generally believed to occur in a multistep process which involves alterations of various tumor suppressor genes and oncogenes during the progression through benign lesions towards carcinoma.
  • TFF3 is a product of the colonic epithelium and has been implicated in colonic mucosal protection and also in the aggressiveness of colon cancer cells.
  • The aim of this study was to analyze the expression of TFF3 during propagation towards cancer development in the human colon.
  • Colonic tissues representing colitis, adenomatous polyposis, tubulovillous adenoma, and mucoid/adeno-carcinomas were processed for immunohistochemistry using an antibody specific for human TFF3.
  • The results were correlated with those of PCNA-labeling, quantified, and compared with those of control tissues obtained from the safe margin of macroscopically normal colonic mucosa of patients with colon cancer.
  • Colonic tissues with highly invasive cancer cells were characterized by statistically significant down-regulation of TFF3 expression.
  • The changes observed in expression of TFF3 showed an inverse correlation with cell proliferation and suggest that it might play a protective role against colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Adenoma, Villous / chemistry. Adenomatous Polyposis Coli / chemistry. Colitis / metabolism. Colonic Neoplasms / chemistry. Peptides / analysis
  • [MeSH-minor] Adult. Cell Proliferation. Cell Transformation, Neoplastic / chemistry. Colon / chemistry. Disease Progression. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Proliferating Cell Nuclear Antigen / analysis. Trefoil Factor-3

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455148.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Peptides; 0 / Proliferating Cell Nuclear Antigen; 0 / TFF3 protein, human; 0 / Trefoil Factor-3
  •  go-up   go-down


56. Ra SH, Fishbein MC, Baruch-Oren T, Shintaku P, Apple SK, Cameron RB, Lai CK: Mucinous adenocarcinomas of the thymus: report of 2 cases and review of the literature. Am J Surg Pathol; 2007 Sep;31(9):1330-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The first case in a 61-year-old woman resembled a mucinous (colloid) carcinoma of other organs such as the breast and colon.
  • It consisted of islands and strips of tumor cells floating in large pools of extracellular mucin.
  • A unique feature of this tumor was the presence of numerous psammoma bodies.
  • Immunohistochemically, the tumor cells were positive for cytokeratin (CK) 7 and negative for CD5.
  • The second case in an 82-year-old woman was a mucinous adenocarcinoma arising from a thymic cyst with areas of transition from benign to dysplastic epithelium.
  • The tumor cells formed dilated glands, cords, and small nests that infiltrated the thymic cyst wall and exhibited evidence of mucin production.
  • Immunohistochemically, the tumor cells were positive for CK 7 and focally positive for both CD5 and CK 5/6.
  • CONCLUSIONS: Mucinous adenocarcinoma, with or without, psammoma bodies, may be of primary thymic origin and should be considered in the differential diagnosis of malignant mediastinal tumors.

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721187.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / KRT5 protein, human; 0 / KRT7 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Keratin-7
  • [Number-of-references] 18
  •  go-up   go-down


57. Modlin IM, Shapiro MD, Kidd M: An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg; 2005 Jan;29(1):92-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of rare carcinoid tumors: clarifying these clinical conundrums.
  • Carcinoid tumors are distinct neuroendocrine neoplasms with characteristic histological, clinical, and biological properties.
  • Though commonly associated with the gastrointestinal tract and bronchopulmonary system, a substantial number of these tumors originate in less common anatomical sites and can range from indolent, unrecognized entities to highly active, metastatic secretory tumors.
  • The authors reviewed 13,715 carcinoid tumors identified by three consecutive registries of the National Cancer Institute (NCI) from 1950 to 1999, focusing on the anatomic sites accounting for less than one percent of all carcinoids.
  • In addition, data from the world's literature published on carcinoid tumors within these particular anatomic locations were then analyzed with respect to incidence, clinical presentation, symptoms, diagnostic evaluation, microscopic and immunohistochemical findings, treatment strategies, and prognosis.
  • The primary organs in which carcinoids are most commonly mistaken for some of the more conspicuous endemic tumors include the esophagus, pancreas, liver, biliary tract, gallbladder, and Meckel's diverticulum, as well as within the pelvic and otolaryngeal organs and the breast.
  • Tumors with the worst prognosis were those that involved the pancreas (37.5%: 5-year survival) and those in the cervix (12-33%: 3-year survival).
  • The diminution of the likelihood of inadvertently neglecting these often benign, indolent neoplasms that are well known to metastasize if unaddressed would represent an important advance.
  • Familiarity with such unusual sites of origin will facilitate appropriate recognition and characterization of such tumors, allowing for timely intervention.
  • [MeSH-major] Carcinoid Tumor / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1996 Mar-Apr;53(2):153-8 [8604242.001]
  • [Cites] Ultrastruct Pathol. 1993 Jan-Feb;17(1):115-21 [8427027.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1241-9 [10189128.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(4):229-35 [7546678.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1705-13 [6383596.001]
  • [Cites] Patol Pol. 1978 Apr-Jun;29(2):237-40 [704186.001]
  • [Cites] N Y State J Med. 1969 May 15;69(10):1337-9 [5255420.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1334-9 [11688471.001]
  • [Cites] Lancet. 1954 Nov 6;267(6845):951 [13213086.001]
  • [Cites] Z Gastroenterol. 1974 Sep;12 Suppl(0):377-84 [4418379.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):897-909 [1707237.001]
  • [Cites] Intern Med. 1996 Dec;35(12 ):953-6 [9030993.001]
  • [Cites] J Urol. 1977 Nov;118(5):777-82 [916100.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2189-95 [10521965.001]
  • [Cites] J Gastroenterol. 1995 Jun;30(3):398-402 [7647908.001]
  • [Cites] Cancer. 1975 Aug;36(2):404-18 [1157010.001]
  • [Cites] Digestion. 1997;58(4):410-4 [9324172.001]
  • [Cites] J Am Coll Surg. 1994 Feb;178(2):187-211 [8173736.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1580-8 [8156484.001]
  • [Cites] Ital J Surg Sci. 1986;16(4):249-53 [3557930.001]
  • [Cites] Gynecol Oncol. 1996 May;61(2):259-65 [8626144.001]
  • [Cites] Thorax. 1989 Jul;44(7):594-6 [2672408.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1476-81 [9118026.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1726-32 [7688660.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):93-5 [7679854.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1109-16 [8758239.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4209-13 [10566674.001]
  • [Cites] Eur J Nucl Med. 1995 Mar;22(3):281-3 [7789401.001]
  • [Cites] Pathol Annu. 1979;14 Pt 1:273-91 [42037.001]
  • [Cites] Diagn Cytopathol. 1989;5(2):217-20 [2776604.001]
  • [Cites] J Gastroenterol. 1999 Feb;34(1):123-7 [10204622.001]
  • [Cites] Zentralbl Allg Pathol. 1959 Jul 25;99:442-4 [14430796.001]
  • [Cites] J Intern Med. 1995 Sep;238(3):281-8 [7673859.001]
  • [Cites] Z Gastroenterol. 1998 Mar;36(3):233-8 [9577907.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Sep;64(3):413-21 [5054879.001]
  • [Cites] J Magn Reson Imaging. 2000 Feb;11(2):141-8 [10713946.001]
  • [Cites] J Urol. 1954 Nov;72(5):892-4 [13212896.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1119-24 [12201876.001]
  • [Cites] Int J Urol. 2001 Sep;8(9):522-4 [11683977.001]
  • [Cites] Histopathology. 1987 Jan;11(1):53-62 [2881873.001]
  • [Cites] J Am Osteopath Assoc. 2000 Jul;100(7):432-4 [10943090.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Hepatogastroenterology. 1998 Sep-Oct;45(23):1462-7 [9840084.001]
  • [Cites] Surgery. 1998 Nov;124(5):831-8 [9823395.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Jul;99(7 Pt 1):547-52 [2164339.001]
  • [Cites] J Laryngol Otol. 1983 Nov;97(11):1073-80 [6644166.001]
  • [Cites] Mod Pathol. 2002 May;15(5):543-55 [12011260.001]
  • [Cites] Acta Oncol. 1993;32(2):225-9 [7686765.001]
  • [Cites] Heart. 1998 Dec;80(6):623-6 [10065036.001]
  • [Cites] Jpn J Clin Oncol. 1989 Dec;19(4):397-401 [2607641.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1959-65 [10570419.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1501-10 [11075851.001]
  • [Cites] Ear Nose Throat J. 2002 Jan;81(1):40-3 [11816388.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1211-8 [2302669.001]
  • [Cites] Ann R Coll Surg Engl. 1959 Dec;25(5):277-97 [19310224.001]
  • [Cites] J Clin Gastroenterol. 1996 Jul;23(1):60-2 [8835904.001]
  • [Cites] Arch Otolaryngol. 1969 Jul;90(1):64-7 [5785991.001]
  • [Cites] Can J Surg. 1999 Feb;42(1):59-63 [10071590.001]
  • [Cites] Acta Cytol. 1990 Mar-Apr;34(2):119-24 [2181800.001]
  • [Cites] Ann Surg Oncol. 1998 Apr-May;5(3):261-4 [9607629.001]
  • [Cites] Diagn Cytopathol. 2001 Sep;25(3):168-71 [11536440.001]
  • [Cites] Pathol Int. 1999 Apr;49(4):318-24 [10365851.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:159-69 [12381551.001]
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):589-96 [1587179.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):609-12 [8631405.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):23-32 [14687136.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Arch Anat Pathol (Paris). 1964 Sep;12:200-3 [14228034.001]
  • [Cites] Am J Clin Pathol. 1980 Jun;73(6):816-23 [6156597.001]
  • (PMID = 15599742.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


58. Fingleton B, Powell WC, Crawford HC, Couchman JR, Matrisian LM: A rat monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized expression in vivo. Hybridoma (Larchmt); 2007 Feb;26(1):22-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunostaining of MMP-7 in normal tissues or benign tumors of intestinal, breast, and prostatic origin indicates that this protein is normally localized luminally in glandular epithelium.
  • The localization pattern would suggest that in normal or early stage tumors, MMP-7 is most likely not directly involved in extracellular matrix degradation.
  • In contrast, advanced colon tumors show MMP-7 in invading cells at the advancing edge of the tumor.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Differentiation. 2002 Dec;70(9-10):561-73 [12492497.001]
  • [Cites] Curr Biol. 1999 Dec 16-30;9(24):1441-7 [10607586.001]
  • [Cites] Cancer Cell. 2005 May;7(5):485-96 [15894268.001]
  • [Cites] Science. 1999 Oct 1;286(5437):113-7 [10506557.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Prostate. 1996 Sep;29(3):159-68 [8827084.001]
  • [Cites] Int J Biochem Cell Biol. 1996 Feb;28(2):123-36 [8729000.001]
  • [Cites] Protein Expr Purif. 1994 Feb;5(1):27-36 [8167471.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1423-47 [15131803.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):119-35 [15000153.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1831-43 [12759241.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Clin Invest. 2000 Jan;105(2):143-50 [10642592.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • (PMID = 17316082.001).
  • [ISSN] 1554-0014
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA60867; United States / NCI NIH HHS / CA / R01 CA84360; United States / NIAMS NIH HHS / AR / AR36457; United States / NCI NIH HHS / CA / R01 CA084360; United States / NIAMS NIH HHS / AR / P30 AR48311; United States / NIAMS NIH HHS / AR / P30 AR048311; United States / NCI NIH HHS / CA / R01 CA100126; United States / NCI NIH HHS / CA / R01 CA060867
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Enzyme Precursors; EC 3.4.24.23 / Matrix Metalloproteinase 7
  • [Other-IDs] NLM/ NIHMS403810; NLM/ PMC3838102
  •  go-up   go-down


59. Littrup PJ, Ahmed A, Aoun HD, Noujaim DL, Harb T, Nakat S, Abdallah K, Adam BA, Venkatramanamoorthy R, Sakr W, Pontes JE, Heilbrun LK: CT-guided percutaneous cryotherapy of renal masses. J Vasc Interv Radiol; 2007 Mar;18(3):383-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These 49 masses included 36 primary renal cell carcinomas (RCCs), 3 oncocytomas, 1 angiomyolipoma, 6 renal inflammatory lesions, 2 benign parenchymal changes, and 1 colon cancer metastasis.
  • All cryotherapy zones were well defined by CT during ablation as hypodense ice with an average diameter of 5.3 cm, covering an average tumor size of 3.3 cm.
  • Average ablation zone diameters showed significant reduction over time (P < .001), becoming significantly less than the original tumor size by 12 months (P < .05).
  • CONCLUSIONS: Percutaneous renal cryotherapy is a well-tolerated outpatient procedure that allows safe, CT monitoring of ice formation beyond visible tumor margins.
  • With appropriate cryoprobe placements, a low failure rate appears less dependent on tumor size or location.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17377184.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-22453
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


60. Wang XP, Li ZJ, Magnusson J, Brunicardi FC: Tissue MicroArray analyses of pancreatic duodenal homeobox-1 in human cancers. World J Surg; 2005 Mar;29(3):334-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In previous studies, we demonstrated that rat insulin promoter (RIP)-driven gene therapy successfully targeted human pancreatic tumor PANC-1 cells and mouse insulinoma NIT-1 cells, which are both pancreatic duodenal homeobox-1 (PDX-1)-positive.
  • The custom-designed Tissue MicroArray of human tumor specimens consists of human cancer specimens from different origins, such as the pancreas, breast, colon, prostate, kidney, liver, lung, and ovary.
  • PDX-1 expression intensity was elevated in both benign and malignant tissues from the same patient with pancreas, breast, colon, prostate, and kidney cancers, whereas normal human tissues from control subjects without cancer did not express PDX-1.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):98-108; discussion 106-8 [14746841.001]
  • [Cites] Surgery. 2003 Aug;134(2):260-6 [12947327.001]
  • [Cites] Surgery. 2000 Aug;128(2):353-60 [10923016.001]
  • [Cites] Cancer Gene Ther. 2001 Nov;8(11):869-78 [11773977.001]
  • [Cites] Gene Ther. 2001 Feb;8(3):199-208 [11313791.001]
  • [Cites] Genes Dev. 1998 Jun 15;12(12):1763-8 [9637677.001]
  • [Cites] Gene Ther. 2000 Mar;7(6):518-26 [10757026.001]
  • [Cites] Pancreas. 2004 Mar;28(2):109-20 [15028942.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Ann Surg. 2001 May;233(5):603-11 [11323498.001]
  • [Cites] Development. 1996 May;122(5):1409-16 [8625829.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Jul;78(7):4458-60 [7027261.001]
  • [Cites] Diabetes. 2003 Jul;52(7):1732-7 [12829640.001]
  • [Cites] J Mol Med (Berl). 1997 May;75(5):327-40 [9181474.001]
  • [Cites] Development. 1989 Apr;105(4):787-94 [2574662.001]
  • [Cites] Diabetes. 2001 Feb;50 Suppl 1:S131-2 [11272171.001]
  • [Cites] Aust N Z J Surg. 1998 Feb;68(2):90-100 [9493997.001]
  • [Cites] World J Surg. 2004 Aug;28(8):826-33 [15457366.001]
  • [Cites] Nat Genet. 1997 Jan;15(1):106-10 [8988180.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4827-36 [11406559.001]
  • [Cites] EMBO J. 1993 Nov;12(11):4251-9 [7901001.001]
  • [Cites] Gut. 2004 Mar;53(3):323-30 [14960508.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25279-86 [11309388.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1416-26 [10579983.001]
  • [Cites] Development. 1995 Jan;121(1):11-8 [7867492.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1688-94 [11527697.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9180-5 [10900262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10332-7 [11526239.001]
  • [Cites] EMBO J. 1994 Mar 1;13(5):1145-56 [7907546.001]
  • [Cites] Nature. 1994 Oct 13;371(6498):606-9 [7935793.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;880:1-4 [10415845.001]
  • [Cites] Semin Gastrointest Dis. 2000 Jul;11(3):162-7 [10950464.001]
  • (PMID = 15706433.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA95731
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein
  •  go-up   go-down


61. Kwon JG, Kim EY, Kim YS, Chun JW, Chung JT, You SS, Ha HK, Lee CH, Kim HG, Cho CH: [Accuracy of endoscopic ultrasonographic impression compared with pathologic diagnosis in gastrointestinal submucosal tumors]. Korean J Gastroenterol; 2005 Feb;45(2):88-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Accuracy of endoscopic ultrasonographic impression compared with pathologic diagnosis in gastrointestinal submucosal tumors].
  • BACKGROUND/AIMS: Endoscopic ultrasonography (EUS) is a valuable imaging modality for the evaluation of gastrointestinal submucosal tumor (SMT).
  • EUS is helpful in assessing the layer of origin, tumor diameter, shape, border characteristics, and internal echo patterns of SMTs and thus makes it possible to predict histologic diagnosis with educated guess.
  • However, some studies have found no significant differences in EUS features between benign and malignant mesenchymal tumors.
  • RESULTS: 34 patients had lesions in the stomach and 13, 8, 3 in the esophagus, duodenum, and colon respectively.
  • Benign lesions were predominant (46 of 58).
  • Use of EUS led to the correct diagnosis in 7/9 (77.8%) of malignant GISTs (gastrointestinal stromal tumor) and leiomyosarcomas.
  • Two small malignant gastric GISTs were diagnosed as benign with EUS.
  • However, some malignant GISTs were diagnosed as benign tumor with EUS examination.
  • [MeSH-minor] Adult. Aged. Biopsy. Diagnosis, Differential. Female. Gastrointestinal Stromal Tumors / diagnostic imaging. Gastrointestinal Stromal Tumors / pathology. Humans. Leiomyosarcoma / diagnostic imaging. Leiomyosarcoma / pathology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725712.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


62. Cui Y, Koop EA, van Diest PJ, Kandel RA, Rohan TE: Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer. Breast Cancer Res Treat; 2007 Jul;104(1):103-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer.
  • Certain nuclear morphometric features measured in breast tumor tissue have been shown to predict the prognosis of breast cancer patients.
  • We conducted a case-control study to evaluate nuclear morphometric features in benign breast tissue in association with subsequent breast cancer risk.
  • The study was nested within a cohort of 4,888 women with a histopathologic diagnosis of benign breast disease (BBD) and involved 61 cases and 71 controls, amongst whom there were 53 matched case-control sets.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microsc Res Tech. 2002 Oct 15;59(2):109-18 [12373721.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):282-5 [11494225.001]
  • [Cites] Histopathology. 2004 Oct;45(4):352-9 [15469473.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):9-18 [7123847.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):603-9 [3722413.001]
  • [Cites] Lab Invest. 1990 Aug;63(2):270-5 [2381167.001]
  • [Cites] Anal Cell Pathol. 1989 Feb;1(1):11-23 [2562217.001]
  • [Cites] Eur J Surg Oncol. 1991 Aug;17(4):350-3 [1874292.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1459-76 [1423087.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1477-88 [1423088.001]
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):374-82 [8908309.001]
  • [Cites] Cancer. 1997 Jun 25;81(3):172-9 [9196016.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):800-5 [9743304.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Urology. 1999 Jan;53(1):44-9 [9886586.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):386-92 [10223762.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(5):257-61 [10392302.001]
  • [Cites] J Pathol. 1999 Feb;187(3):272-8 [10398078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):768-72 [15824141.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):297-9 [16034016.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3542-8 [10589770.001]
  • [Cites] Pathol Res Pract. 1999;195(11):741-6 [10605693.001]
  • [Cites] Pol J Pathol. 1999;50(4):235-41 [10721263.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):494-9 [11102893.001]
  • [Cites] J Pathol. 2001 Jan;193(1):33-9 [11169513.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):249-59 [11303595.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):836-41 [12766590.001]
  • (PMID = 17061043.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2092407
  •  go-up   go-down


63. Yang BL, Gu YF, Shao WJ, Chen HJ, Sun GD, Jin HY, Zhu X: Retrorectal tumors in adults: magnetic resonance imaging findings. World J Gastroenterol; 2010 Dec 14;16(46):5822-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrorectal tumors in adults: magnetic resonance imaging findings.
  • AIM: To retrospectively evaluate the magnetic resonance imaging (MRI) features of adult retrorectal tumors and compare with histopathologic findings.
  • METHODS: MRI features of 21 patients with preoperative suspicion of retrorectal tumors were analyzed based on the histopathological and clinical data.
  • RESULTS: Fourteen benign cystic lesions appeared hypointense on T1-weighted images, and hyperintense on T2-weighted images with regular peripheral rim.
  • Six solid tumors were malignant lesions and showed heterogeneous intensity on MRI.
  • Gastrointestinal stromal tumors displayed low signal intensity on T1-weighted images, and intermediate to high signal intensity on T2-weighted images.
  • CONCLUSION: MRI is a helpful technique to define the extent of the retrorectal tumor and its relationship to the surrounding structures, and also to demonstrate possible complications so as to choose the best surgical approach.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):855-8 [4053899.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1926-9 [15300393.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):495-9 [8233293.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):731-2 [9294562.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jun;170(6):1488-90 [9609159.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):1056-8 [9715165.001]
  • [Cites] Clin Imaging. 2005 Jul-Aug;29(4):251-4 [15967315.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1581-7 [15937630.001]
  • [Cites] Yonsei Med J. 2005 Aug 31;46(4):555-61 [16127782.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):517-21 [16861558.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):381-5 [16909248.001]
  • [Cites] Br J Surg. 2008 Feb;95(2):214-21 [17933000.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):498-500 [17680300.001]
  • [Cites] Eur Radiol. 2008 Nov;18(11):2586-93 [18566821.001]
  • [Cites] Can J Surg. 2008 Dec;51(6):E115-6 [19057717.001]
  • [Cites] Am Surg. 2009 Mar;75(3):240-8 [19350861.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1344-7 [10811351.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):575-84 [11353107.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):705-14 [12023574.001]
  • [Cites] Tech Coloproctol. 2002 Apr;6(1):43-9 [12077641.001]
  • [Cites] Hum Pathol. 2002 May;33(5):456-8 [12094369.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] Surg Oncol. 2003 Jul;12(1):21-6 [12689667.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):55-7 [12750956.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):880-6 [12788424.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):2053-4 [12942309.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • (PMID = 21155003.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3001973
  •  go-up   go-down


64. Schildhaus HU, Merkelbach-Bruse S, Binot E, Büttner R, Wardelmann E: [Inflammatory fibroid polyp: from Vanek's "submucosal granuloma" to the concept of submucosal mesenchymal neoplasia]. Pathologe; 2010 Mar;31(2):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inflammatory fibroid polyp: from Vanek's "submucosal granuloma" to the concept of submucosal mesenchymal neoplasia].
  • IFP represent polypous proliferations of spindle cells in the submucosa and mucosa of the stomach, small bowel and colon with inflammatory infiltration.
  • Therefore, IFP represent true benign mesenchymal tumors of the gastrointestinal tract.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. DNA Mutational Analysis. Diagnosis, Differential. Gastric Mucosa / pathology. Gastritis / pathology. Gastrointestinal Stromal Tumors / genetics. Gastrointestinal Stromal Tumors / pathology. Helicobacter Infections / genetics. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Intestinal Mucosa / pathology. Receptor, Platelet-Derived Growth Factor alpha / genetics. Sequence Analysis, DNA. Sequence Analysis, Protein

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Gastroenterol Hepatol. 2009 Jun;6(6):331-41 [19421245.001]
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):767-8 [14991958.001]
  • [Cites] Am J Pathol. 1949 May;25(3):397-411 [18127133.001]
  • [Cites] Gut. 1992 Jul;33(7):1004-5 [1644320.001]
  • [Cites] Mod Pathol. 2009 Aug;22(8):1049-56 [19448595.001]
  • [Cites] Pathologe. 2009 Dec;30 Suppl 2:117-20 [19756614.001]
  • [Cites] Lab Invest. 2006 Jan;86(1):94-100 [16258521.001]
  • [Cites] Intern Med. 2007;46(12):855-8 [17575378.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] J Pathol. 2008 Oct;216(2):176-82 [18686281.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5357-64 [15928335.001]
  • [Cites] Histopathology. 2005 Feb;46(2):166-75 [15693889.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1907-12 [17087943.001]
  • [Cites] J Pathol. 2007 Jun;212(2):227-35 [17471466.001]
  • [Cites] Endoscopy. 1990 Sep;22(5):203-7 [2242737.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1412-20 [18670346.001]
  • [Cites] Surg Gynecol Obstet. 1953 Mar;96(3):335-67 [13038651.001]
  • [Cites] Pathol Res Pract. 1981 May;171(3-4):336-44 [7279785.001]
  • [Cites] Diagn Cytopathol. 2003 Apr;28(4):217-21 [12672099.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):874-83 [15146165.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):197-204 [15269295.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):664-71 [16357008.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Mar;12(1):59-66 [15163021.001]
  • (PMID = 20107807.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 23
  •  go-up   go-down


65. Gonçalves AJ, Carvalho LH, Serdeira K, Nakai MY, Malavasi TR: Comparative analysis of the prevalence of the glutathione S-transferase (GST) system in malignant and benign thyroid tumor cells. Sao Paulo Med J; 2007 Sep 6;125(5):289-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of the prevalence of the glutathione S-transferase (GST) system in malignant and benign thyroid tumor cells.
  • CONTEXT AND OBJECTIVE: When null, the mu and theta genes of the glutathione S-transferase system (GSTM1 and GSTT1, respectively) are related to malignant tumors affecting the lungs, colon, prostate, bladder and head and neck.
  • The aim of this study was to compare the frequencies of these genes in patients with benign and malignant tumors of the thyroid gland.
  • DESIGN AND SETTINGS: This was a cross-sectional clinical trial carried out in the Head and Neck Surgery Division, Faculdade de Medicina da Santa Casa de São Paulo.
  • METHODS: Samples of thyroid tissue were collected from 32 patients and divided into two groups: benign tumor (A) and malignant tumor (B).
  • CONCLUSION: In this study, there was no relationship between the presence of the GSTT1 and GSTM1 genes and the benign and malignant thyroid tumors.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Cross-Sectional Studies. Female. Genotype. Humans. Male

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094897.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


66. Achiam MP, Andersen LP, Klein M, Løgager V, Chabanova E, Thomsen HS, Rosenberg J: Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study. Eur J Radiol; 2010 Jun;74(3):e45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study.
  • BACKGROUND: Colorectal cancer will present itself as a bowel obstruction in 16-23% of all cases.
  • However, not all obstructing tumors are malignant and the differentiation between a benign and a malignant tumor can be difficult.
  • The purpose of our study was to determine whether fast dynamic gadolinium-enhanced MR imaging combined with MR colonography could be used to differentiate a benign from a malignant obstructing colon tumor.
  • METHODS: Patients with benign colon tumor stenosis, based on diverticulitis, were asked to participate in the study.
  • Two blinded observers analyzed the tumors on MR by placing a region of interest in the tumor and a series of parameters were evaluated, e.g. wash-in, wash-out and time-to-peak.
  • The wash-in and wash-out rates were significantly different between the benign and malignant tumors, and a clear distinction between benign and malignant disease was therefore possible by looking only at the MR data.
  • Furthermore, MR colography evaluating the rest of the colon past the stenosis was possible with all patients.
  • CONCLUSION: The results showed the feasibility of using fast dynamic gadolinium-enhanced MR imaging to differentiate between benign and malignant colonic tumors.
  • With a high intra-class correlation and significant differences found on independent segments of the tumor, the method appears to be reproducible.
  • Furthermore, the potential is big in performing a full preoperative colon evaluation even in patients with obstructing cancer.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Diverticulitis / diagnosis. Diverticulitis / etiology. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Meglumine. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19419830.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00114829
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


67. Hague A, Hicks DJ, Hasan F, Smartt H, Cohen GM, Paraskeva C, MacFarlane M: Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer; 2005 Feb 28;92(4):736-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The death ligand TRAIL (Apo2L) has potential for cancer therapy, since tumour cells are thought to be more sensitive than normal cells.
  • This finding was recapitulated in an in vitro model of tumour progression in which conversion of the adenoma cell line AA/C1 to a tumorigenic phenotype was associated with increased TRAIL sensitivity (P<0.001).
  • In summary, during colorectal carcinogenesis, there is a marked increase in sensitivity to TRAIL-induced apoptosis associated with progression from benign to malignant tumour that could be exploited for colon cancer therapy, but alterations in cell surface TRAIL receptor expression may not be the primary reason for this change.
  • [MeSH-major] Adenoma / pathology. Apoptosis. Carcinoma / pathology. Cell Transformation, Neoplastic. Colorectal Neoplasms / pathology. Membrane Glycoproteins / metabolism. Receptors, Tumor Necrosis Factor / metabolism. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Apoptosis Regulatory Proteins. Blotting, Western. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Flow Cytometry. GPI-Linked Proteins. Humans. Mice. Mice, Nude. Receptors, TNF-Related Apoptosis-Inducing Ligand. TNF-Related Apoptosis-Inducing Ligand. Tumor Necrosis Factor Decoy Receptors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Mar 27;22(12):1807-16 [12660816.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3734-40 [12473583.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8628-33 [14634624.001]
  • [Cites] Histopathology. 2004 Mar;44(3):240-6 [14987227.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):594-604 [15196850.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35829-39 [15155747.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6666-72 [15374982.001]
  • [Cites] Cell Death Differ. 2004 Oct;11(10):1084-91 [15243584.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4562-9 [1000501.001]
  • [Cites] Int J Cancer. 1984 Jul 15;34(1):49-56 [6746117.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1282-6 [2917357.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4724-30 [2369746.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):785-90 [1428233.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):498-505 [8397167.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):346-7 [8090205.001]
  • [Cites] J Cell Sci. 1994 Dec;107 ( Pt 12):3569-77 [7706406.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12687-90 [8663110.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):898-905 [9311611.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25417-20 [9325248.001]
  • [Cites] Immunity. 1997 Dec;7(6):813-20 [9430226.001]
  • [Cites] Immunity. 1997 Dec;7(6):821-30 [9430227.001]
  • [Cites] Immunity. 1997 Dec;7(6):831-6 [9430228.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):2833-40 [9743343.001]
  • [Cites] J Biol Chem. 1998 Dec 4;273(49):33091-8 [9830064.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):629-30 [9872307.001]
  • [Cites] Nat Med. 1999 Feb;5(2):146-7 [9930856.001]
  • [Cites] Cancer Lett. 1998 Nov 27;133(2):197-204 [10072170.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2597-605 [10072501.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4153-9 [10435597.001]
  • [Cites] Oncogene. 2001 Mar 22;20(12):1476-85 [11313891.001]
  • [Cites] FEBS Lett. 2002 Jan 2;510(1-2):37-40 [11755527.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):659-66 [11874999.001]
  • [Cites] Int J Oncol. 2002 Sep;21(3):643-8 [12168112.001]
  • [Cites] Oncogene. 2002 Oct 3;21(44):6809-18 [12360407.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6153-8 [10626806.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):335-46 [10690508.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1239-54 [10725337.001]
  • [Cites] J Immunol. 2000 Apr 15;164(8):3961-70 [10754286.001]
  • [Cites] Biochem J. 2000 May 15;348 Pt 1:93-101 [10794718.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1645-51 [11245478.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):409-16 [11283615.001]
  • [Cites] J Pathol. 2003 Jul;200(3):327-35 [12845629.001]
  • (PMID = 15685228.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human; 0 / TNFRSF10B protein, human; 0 / TNFRSF10C protein, human; 0 / TNFSF10 protein, human; 0 / Tnfrsf10b protein, mouse; 0 / Tnfsf10 protein, mouse; 0 / Tumor Necrosis Factor Decoy Receptors; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2361885
  •  go-up   go-down


68. Suzuki H, Graziano DF, McKolanis J, Finn OJ: T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res; 2005 Feb 15;11(4):1521-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Cyclin B1-derived peptides were shown by us to be targets of tumor-specific CD8(+) T cells in patients with breast and head and neck cancer.
  • We obtained further evidence of cyclin B1 immunogenicity and its potential to serve as a tumor-specific antigen by analyzing its ability to elicit T cell-dependent humoral immune responses in vivo in patients with different types of tumors.
  • EXPERIMENTAL DESIGN: Recombinant cyclin B1 protein from two different sources was purified and used as antigen in ELISA assays to test sera from patients with breast, pancreatic, colon, and lung cancer for the presence of anti-cyclin B1 antibody.
  • We also analyzed patients with benign lung disease, premalignant disease, and a known history of heavy smoking.
  • Tumors with higher level of cyclin B1 expression elicit higher anti-cyclin B1 antibody levels.
  • Antibodies in patients with breast and colon cancer are primarily of the IgG isotype whereas patients with pancreatic and lung cancer have in addition anti-cyclin B1 IgA.
  • Immune responses to aberrantly expressed cyclin B1 in tumors and premalignant lesions should be further explored as diagnostic and prognostic markers, in addition to their immunotherapeutic potential.
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / immunology. Breast Neoplasms / metabolism. Colonic Neoplasms / blood. Colonic Neoplasms / immunology. Colonic Neoplasms / metabolism. Cyclin B1. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunohistochemistry. Lung Neoplasms / blood. Lung Neoplasms / immunology. Lung Neoplasms / metabolism. Male. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / immunology. Pancreatic Neoplasms / metabolism. Smoking / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746055.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 090440
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNB1 protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / Immunoglobulin A; 0 / Immunoglobulin G
  •  go-up   go-down


69. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


70. Colović R, Grubor N, Radak V, Micev M, Stojković M, Colović N: [Aggressive intraabdominal fibromatosis]. Vojnosanit Pregl; 2006 Sep;63(9):839-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intraabdominal or mesenteric fibromatosis is a rare benign nonmetastatic neoplasm that appears as a sporadic lesion or in patients with familiar polyposis.
  • CASE REPORT: We presented a 22-year-old woman in whom an aggressive intraabdominal fibromatosis had appeared during the first pregnancy as a well circumscribed ovoid tumor, involving the terminal ileum, the caecum, the ascending colon, the right kidney, the ureter, and the right common iliac artery.
  • The tumor was excised with right colectomy, nephroureterectomy and resection of the involved artery using arterial reconstruction with graft interposition.
  • Two years after the surgery the patient developed an inoperable tumor recurrency with a fatal outcome.
  • CONCLUSION: In spite of a successful surgical excision during the original surgery intraabdominal or mesenteric fibromatosis might have an aggressive evolution leading to an inoperable tumor recurrency and a fatal outcome.
  • [MeSH-major] Fibromatosis, Abdominal / pathology. Fibromatosis, Aggressive / pathology. Neoplasm Recurrence, Local. Pregnancy Complications, Neoplastic / pathology


71. Di Valentino M, Menafoglio A, Mazzucchelli L, Siclari F, Gallino A: Rapid-growing left intraventricular cardiac hemangioma. J Am Soc Echocardiogr; 2006 Jul;19(7):939.e5-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62 years old man with Child B liver cirrhosis, prostate cancer and a recent colon carcinoma resection was referred to our cardiology department for trans-thoracic-echocardiography (TTE) in order to establish left ventricular function before starting chemotherapy.
  • At follow-up TTE showed growing of the intra-cardiac tumor up to 27 x 10 mm, corresponding to a size increase of 1 mm/month.
  • Among different pathologies a rapid growing benign tumor with a high risk of systemic embolisation or an endocardial blood cyst were retained as possible diagnoses.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825010.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Gravante G, Delogu D, Venditti D: Colosigmoid adenocarcinoma anastomotic recurrence seeding into a transsphincteric fistula-in-ano: a clinical report and literature review. Surg Laparosc Endosc Percutan Tech; 2008 Aug;18(4):407-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the case of a left colon adenocarcinoma anastomotic recurrence that metastasized to a benign transsphincteric fistula-in-ano, presumably through the implantation of viable malignant cells shed from the secondary tumor, and discuss the implications of these findings in colorectal cancer surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Recurrence, Local / pathology. Neoplasm Seeding. Rectal Fistula / pathology. Rectal Neoplasms / secondary. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716545.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


73. Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J: Tumor microenvironment and progression of pancreatic cancer. Exp Oncol; 2010 Sep;32(3):128-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor microenvironment and progression of pancreatic cancer.
  • Pancreatic ductal adenocarcinoma is characterized by « tumor desmoplasia », a remarkable increase in connective tissue that penetrates and envelopes the neoplasm.
  • It is becoming clear that this desmoplastic microenvironment of pancreatic cancer--which is forming approximately eighty percent of the tumor mass--is not a passive scaffold for the tumor cells but an active player in carcinogenesis.
  • Several chemotherapeutic agents and novel molecular targeted therapies against epithelial tumor cells--although showing antitumor activity in cell culture and mouse experiments--have failed to show significant effects in the clinic.
  • Thus, targeting pancreatic tumor cells alone seems unlikely to improve the dismal prognosis of pancreatic cancer.
  • Several primarily benign conditions associated with expansion of stromal and inflammatory components, such as chronic pancreatitis or hereditary pancreatitis are believed to increase the risk of pancreatic cancer.
  • Similar observations have been made in other cancer types such as chronic hepatitis-liver cancer, Barrett dyplasia-esophageal cancer, and inflammatory bowel disease-colon cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Pancreas / pathology. Pancreatic Neoplasms / metabolism. Tumor Microenvironment

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21403605.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ukraine
  •  go-up   go-down


74. Moussi A, Nouira R, Bourguiba B, Daldoul S, Zaouche A: A rare cause of lower gastrointestinal bleeding. Tunis Med; 2010 Dec;88(12):961-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Leiomyoma of the colon are rare benign smooth muscle tumours.
  • The colonoscopy showed an active bleeding from the right colon but it was enable to specify the nature and the exact seat of the bleeding lesion.
  • An emergent operation showed a tumor of the right colic angle of 8 cm.
  • CONCLUSION: Colic leiomyomas are rare benign tumours.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Gastrointestinal Hemorrhage / etiology. Leiomyoma / diagnosis

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21136371.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


75. Hornick JL, Fletcher CD: Intestinal perineuriomas: clinicopathologic definition of a new anatomic subset in a series of 10 cases. Am J Surg Pathol; 2005 Jul;29(7):859-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign peripheral nerve sheath tumors are uncommon in the gastrointestinal tract, and perineuriomas have not previously been reported to occur at this anatomic location.
  • The remaining 2 cases were submucosal masses, one each located in the colon and jejunum.
  • Of the mucosal polyps, six were located in the rectosigmoid or sigmoid colon and one each was detected in the descending colon and transverse colon.
  • The colonic and jejunal masses measured 3 cm and 4.5 cm, respectively.
  • The lesions had a fine collagenous stroma, demonstrated irregular borders with the adjacent lamina propria, and entrapped colonic crypts.
  • The colonic submucosal tumor was microscopically well circumscribed, whereas the jejunal perineurioma showed focal infiltration through the muscularis propria into the subserosa.
  • The stroma was collagenous in the colonic tumor and predominantly myxoid in the jejunal tumor.
  • All tumors except one were positive for epithelial membrane antigen (EMA); 4 of 10 expressed claudin-1 and 2 of 10 expressed CD34.
  • All tumors were negative for S-100 protein, glial fibrillary acidic protein, neurofilament protein, smooth muscle actin, desmin, caldesmon, KIT, and pan-keratin.
  • Electron microscopy was performed on the tumor lacking EMA expression, revealing typical features of perineurioma, namely, spindle cells with long bipolar cytoplasmic processes and prominent pinocytotic vesicles, surrounded by discontinuous basal lamina.
  • No tumor recurred.
  • In summary, perineuriomas may arise in the intestine, most often as intramucosal lesions detected as colorectal polyps with distinctive histologic features including entrapment of colonic crypts.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2006 Oct;30(10):1337-9 [17001168.001]
  • (PMID = 15958849.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 26
  •  go-up   go-down


76. Kan H, Suzuki H, Shinji S, Naito Z, Furukawa K, Tajiri T: Case of an inflammatory fibroid polyp of the cecum. J Nippon Med Sch; 2008 Jun;75(3):181-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An inflammatory fibroid polyp (IFP) is a rare benign lesion, originating in the submucosa of the gastrointestinal tract.
  • It typically arises in the stomach and small intestine but also arises infrequently in the colon.
  • The lesion was diagnosed to be a submucosal tumor.
  • Immunohistochemical staining of the spindle-shaped cells, which were present around the small vessels in the stroma of the tumor, showed that the tissue expressed vimentin but not alpha-smooth muscle actin, desmin, S-100, c-kit or CD 34.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648178.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Pickhardt PJ, Kim DH, Taylor AJ, Gopal DV, Weber SM, Heise CP: Extracolonic tumors of the gastrointestinal tract detected incidentally at screening CT colonography. Dis Colon Rectum; 2007 Jan;50(1):56-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracolonic tumors of the gastrointestinal tract detected incidentally at screening CT colonography.
  • PURPOSE: The aim of this article is to report our experience with incidental detection of extracolonic tumors of the gastrointestinal tract identified prospectively at screening CT colonography.
  • Following cathartic preparation and colonic distention, supine and prone multidetector CT scans were obtained with thin-collimation low-dose technique without intravenous contrast.
  • Tumor locations included ileum (n = 3), stomach (n = 3), jejunum (n = 2), and appendix (n = 2).
  • Mean tumor size was 2.2 (range, 0.8-3.4) cm.
  • Final diagnoses were benign in all cases and included lipoma (n = 3), small-bowel hamartoma (n = 2), appendiceal mucinous cystadenoma (n = 2), gastric leiomyoma (n = 1), small-bowel lymphangioma (n = 1), and gastric fundic gland polyp (n = 1).
  • CONCLUSIONS: Incidental extracolonic tumors of the gastrointestinal tract detected at screening CT colonography were all asymptomatic and benign but often prompted more invasive workup.
  • Although the incidence of these tumors was relatively low, widespread population screening with CT colonography would result in new surgical referrals for these findings.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115333.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Zamir N, Ahmed S, Akhtar J: Mucinous adenocarcinoma of colon. APSP J Case Rep; 2010 Jul;1(2):20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of colon.
  • Bleeding per rectum is a common complaint in pediatric age group and mostly relates to benign conditions.
  • We report two cases of mucinous adenocarcinoma of colon, one in a 9 years old male and other in a female of 12 years.
  • He had mucinous adenocarcinoma (T3N0MX) of rectosigmoid region and underwent local complete resection of the tumor with colostomy.
  • He is tumor free at two years follow up.
  • The girl presented with signs of intestinal obstruction and at colonoscopy a stricture found in descending colon.
  • The tumor was resected and biopsy reported as poorly differentiated mucinous adenocarcinoma with positive mesenteric nodes positive for tumor (T3N2MX).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Postgrad Med. 1993 Oct-Dec;39(4):218-9 [7527858.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1499-504 [10549756.001]
  • [Cites] Indian Pediatr. 2001 Aug;38(8):933-4 [11521016.001]
  • [Cites] Paediatr Drugs. 2008;10(3):177-92 [18454570.001]
  • [Cites] Indian J Cancer. 2008 Jul-Sep;45(3):119-22 [19018116.001]
  • [Cites] Afr J Paediatr Surg. 2009 Jan-Jun;6(1):65-7 [19661674.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5808-14 [18089879.001]
  • [Cites] J Ayub Med Coll Abbottabad. 2007 Jul-Sep;19(3):56-63 [18444593.001]
  • (PMID = 22953263.001).
  • [ISSN] 2218-8185
  • [Journal-full-title] APSP journal of case reports
  • [ISO-abbreviation] APSP J Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Other-IDs] NLM/ PMC3417995
  • [Keywords] NOTNLM ; Bleeding per rectum / Child / Mucinous adenocarcinoma / Colorectum
  •  go-up   go-down


79. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol; 2010;8:147
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent data provide significant evidence to support the hypothesis that there are sub-populations of cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
  • CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas, ovary and endometrium.
  • Our objectives were to assess the relative level of CD133 expressing cells in primary human endometrial tumors, confirm their tumorigenic potential, and determine whether CD133 expression was epigenetically modified.
  • METHODS: We assessed CD133 expression in primary human endometrial tumors by flow cytometry and analyzed the relative tumorigenicity of CD133+ and CD133- cells in an in vivo NOD/SCID mouse model.
  • We further examined CD133 promoter methylation and expression in normal endometrium and malignant tumors.
  • In addition, we confirmed the tumor initiating potential of CD133+ and CD133- cell fractions in NOD/SCID mice.
  • Interestingly, the percentage of CD133+ cells in human endometrial tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend was not consistently detected by flow cytometry.
  • To support this finding, we demonstrated that regions of the CD133 promoter were hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue.
  • Lastly, we determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor xenograft.
  • [MeSH-minor] Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Oct;18(10):1037-46 [18679414.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8094-103 [18829568.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Biol Reprod. 2009 Jun;80(6):1136-45 [19228591.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2235-7 [19528487.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [19509143.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8241-8 [19843861.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2405-13 [19658191.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] J Biochem. 2010 Sep;148(3):273-80 [20551139.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1516-29 [20800872.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):227-42 [11174845.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1738-50 [14766732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Biol Reprod. 1989 Mar;40(3):681-90 [2758097.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):45-51 [16923745.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1214-23 [17283036.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 [17868344.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • (PMID = 21122138.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3027593
  •  go-up   go-down


80. Bonin EA, Baron TH: Update on the indications and use of colonic stents. Curr Gastroenterol Rep; 2010 Oct;12(5):374-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the indications and use of colonic stents.
  • Self-expandable metal stent (SEMS) placement is a minimally invasive option for achieving acute colonic decompression in obstructed colorectal cancer.
  • Colorectal stenting offers nonoperative, immediate, and effective colon decompression and allows bowel preparation for an elective oncologic resection.
  • Colonic stent placement also offers effective palliation of malignant colonic obstruction, although it carries risks of delayed complications.
  • Despite concerns of tumor seeding following endoscopic colorectal stent placement, no difference exists in oncologic long-term survival between patients who undergo stent placement followed by elective resection and those undergoing emergency bowel resection.
  • Colorectal stents have also been used in selected patients with benign colonic strictures.
  • Patients with benign colonic stricture with acute colonic obstruction who are at high risk for emergency surgery can gain temporary relief of obstruction after SEMS placement; the stent can be removed en bloc with the colon specimen at surgery.
  • This article reviews the techniques and indications of SEMS placement for benign and malignant colorectal obstructions.
  • [MeSH-minor] Acute Disease. Colon / pathology. Colon / surgery. Colonic Diseases / etiology. Colonic Diseases / surgery. Constriction, Pathologic / surgery. Humans. Palliative Care. Pelvic Neoplasms / complications. Pelvic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2009 Oct;19(5):e202-5 [19851253.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2009 Feb;11(2):178-83 [18477021.001]
  • [Cites] Lancet. 2006 Nov 4;368(9547):1573-4 [17084754.001]
  • [Cites] Scand J Surg. 2009;98(3):143-7 [19919918.001]
  • [Cites] J Gastrointest Surg. 2009 May;13(5):960-5 [19159986.001]
  • [Cites] South Med J. 2009 Dec;102(12):1257-9 [20016435.001]
  • [Cites] World J Surg. 2009 Jun;33(6):1281-6 [19363580.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):68-73 [18028916.001]
  • [Cites] J Am Coll Surg. 2001 Jun;192(6):719-25 [11400965.001]
  • [Cites] Brachytherapy. 2009 Jul-Sep;8(3):313-7 [19211311.001]
  • [Cites] Can J Gastroenterol. 2006 Dec;20(12):779-85 [17171197.001]
  • [Cites] Arch Surg. 2009 Dec;144(12):1127-32 [20026830.001]
  • [Cites] Surg Endosc. 2007 Feb;21(2):225-33 [17160651.001]
  • [Cites] Gastrointest Endosc. 2010 Apr;71(4):799-805 [20363422.001]
  • [Cites] Gastrointest Endosc. 2010 Mar;71(3):560-72 [20189515.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jul;193(1):248-54 [19542421.001]
  • [Cites] Dis Colon Rectum. 2003 Jan;46(1):24-30 [12544518.001]
  • [Cites] World J Gastroenterol. 2007 Aug 7;13(29):3977-80 [17663513.001]
  • [Cites] Curr Oncol Rep. 2009 Jul;11(4):293-7 [19508834.001]
  • [Cites] Curr Opin Gastroenterol. 2009 Jan;25(1):50-4 [19119510.001]
  • [Cites] Scand J Gastroenterol. 2010 Jun;45(6):725-31 [20205505.001]
  • [Cites] Colorectal Dis. 2009 May;11(4):405-9 [18513190.001]
  • [Cites] Radiology. 2010 Mar;254(3):774-82 [20177092.001]
  • [Cites] Dis Colon Rectum. 2009 Sep;52(9):1657-61 [19690497.001]
  • [Cites] Dis Colon Rectum. 2009 Jul;52(7):1272-7 [19571704.001]
  • [Cites] J Am Coll Surg. 2010 Jan;210(1):45-53 [20123331.001]
  • [Cites] BMC Surg. 2007 Jul 03;7:12 [17608947.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Am Surg. 2009 Oct;75(10):897-900 [19886130.001]
  • [Cites] Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):399-409 [19072388.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 May;21(5):585-6 [19282771.001]
  • [Cites] Dig Dis Sci. 2010 Jun;55(6):1732-7 [19693667.001]
  • [Cites] Surg Endosc. 2010 Mar;24(3):525-30 [19597776.001]
  • [Cites] Colorectal Dis. 2011 May;13(5):549-54 [20082633.001]
  • [Cites] Dis Colon Rectum. 2010 Feb;53(2):200-12 [20087096.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2007 Apr;17(2):323-39, vi [17556151.001]
  • [Cites] Gastrointest Endosc. 2009 Jun;69(7):1282-7 [19286179.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2051-7 [15447772.001]
  • [Cites] Gastrointest Endosc. 2009 Mar;69(3 Pt 2):675-80 [19251009.001]
  • [Cites] Surgery. 2008 Nov;144(5):786-92 [19081022.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Nov;7(11):1174-6 [19631290.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):1-7 [15672048.001]
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1007-12 [18594837.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):921-4 [17140899.001]
  • [Cites] Am J Gastroenterol. 2010 May;105(5):1087-93 [19935785.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):454-62 [17704890.001]
  • (PMID = 20703837.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


81. Van Patten K, Parkash V, Jain D: Cadherin expression in gastrointestinal tract endometriosis: possible role in deep tissue invasion and development of malignancy. Mod Pathol; 2010 Jan;23(1):38-44